<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SMM</journal-id>
<journal-id journal-id-type="hwp">spsmm</journal-id>
<journal-id journal-id-type="nlm-ta">Stat Methods Med Res</journal-id>
<journal-title>Statistical Methods in Medical Research</journal-title>
<issn pub-type="ppub">0962-2802</issn>
<issn pub-type="epub">1477-0334</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0962280211432210</article-id>
<article-id pub-id-type="publisher-id">10.1177_0962280211432210</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
<xref ref-type="corresp" rid="corresp1-0962280211432210"/>
</contrib>
<aff id="aff1-0962280211432210">Medical Statistics Group, ScHARR, University of Sheffield, Sheffield, UK</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0962280211432210">Steven A Julious, Medical Statistics Group, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. Email: <email>S.A.Julious@Sheffield.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>2</issue>
<issue-title>Special Issue: Meta analysis in Clinical Research</issue-title>
<fpage>190</fpage>
<lpage>218</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>A number of meta-analyses have been undertaken to assess both the safety and efficacy of antidepressants in paediatric and adolescent patients. This article updates the analyses with additionally reported trials. The aim of this analysis was to investigate whether antidepressant treatments are associated with an increased risk of suicide-related outcomes in paediatric and adolescent patients. Also, in the same population, to assess whether antidepressant treatments are beneficial in terms of efficacy. A meta-analysis of randomised controlled trials of antidepressant treatments compared with placebo in paediatric and adolescent patients was undertaken of 6039 individuals participating in 35 randomised controlled trials. For suicide-related outcomes suicidal behaviour, suicidal ideation and suicidal behaviour or ideation were examined. These data presented the additional problem of the events of interest being rare. An analysis was described in this article to account for the rare events that also included studies which had no events on either treatment arm. There were trends to indicate that active treatments increased the risk of these events in absolute terms. For efficacy, the results indicated that antidepressant treatments did have a statistically significant effects compared to placebo but the effect was less for the trials in depression. The results are in the main consistent with previous meta-analyses on a smaller number of trials. There was evidence of an increased risk in suicide-related outcomes on antidepressant treatments, while antidepressant treatments were also shown to be efficacious.</p>
</abstract>
<kwd-group>
<kwd>Efficacy</kwd>
<kwd>meta-analysis</kwd>
<kwd>SSRIs</kwd>
<kwd>suicide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0962280211432210" sec-type="intro"><title>1 Introduction</title>
<p>In 2004, the Food and Drug Administration (FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup>) in the USA undertook a meta-analysis of paediatric and adolescent suicide data. The FDA analysis was subsequently published,<sup><xref ref-type="bibr" rid="bibr2-0962280211432210">2</xref></sup> re-analysed<sup><xref ref-type="bibr" rid="bibr3-0962280211432210">3</xref>,<xref ref-type="bibr" rid="bibr4-0962280211432210">4</xref></sup> and discussed.<sup><xref ref-type="bibr" rid="bibr5-0962280211432210">5</xref>–<xref ref-type="bibr" rid="bibr7-0962280211432210">7</xref></sup> In light of these analyses, the FDA issued a ‘Black Box’ warning on the risk of suicidality and antidepressant drugs in children and young adults,<sup><xref ref-type="bibr" rid="bibr8-0962280211432210">8</xref></sup> while the Committee on the Safety of Medicines stated that, with the exception of Fluoxetine, the balance of risk to benefit was not favourable in paediatric or adolescent patients.<sup><xref ref-type="bibr" rid="bibr9-0962280211432210">9</xref></sup></p>
<p>In adult patients, the evidence as to the risk of suicide was equivocal in a meta-analysis of clinical trials.<sup><xref ref-type="bibr" rid="bibr10-0962280211432210">10</xref></sup> In a case control study, similar results were found for adults but there was weak evidence that there may be an increase in risk for patients aged 18 or under.<sup><xref ref-type="bibr" rid="bibr11-0962280211432210">11</xref></sup></p>
<p>Three meta-analyses have been conducted to assess the efficacy of selective serotonin reuptake inhibitors (SSRIs) in adolescents and children.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref>–<xref ref-type="bibr" rid="bibr14-0962280211432210">14</xref></sup> These studies themselves built on the analyses of the FDA which analysed the safety of serotonin reuptake inhibitors (SSRIs) and atypical regimens.<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref>,<xref ref-type="bibr" rid="bibr2-0962280211432210">2</xref></sup> This article will build on the meta-analyses of the first two studies with an update trial database of 35 studies.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref>,<xref ref-type="bibr" rid="bibr13-0962280211432210">13</xref></sup></p>
<p>One issue with the analysis of suicide data is that the events being investigated are rare. This raises two questions as to how to analyse the data. The first is the appropriate scale for the analysis – an absolute scale (such as in Ref.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup>) or a relative scale (such as in Ref.<sup><xref ref-type="bibr" rid="bibr2-0962280211432210">2</xref></sup>). The second is how to consider the studies where there were no events – to ignore them (such as in Ref.<sup><xref ref-type="bibr" rid="bibr2-0962280211432210">2</xref></sup>) or to include them by an approach such as adding a half to all the cells (such as in Ref.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup>).</p>
<p>This article has two objectives. First to investigate the suicide – as determined by suicidal behaviour, suicidal ideation and suicidal behaviour or ideation – of antidepressants in adolescents and children with methods proposed that account for rare events. Second to investigate efficacy data using methods that account for the different clinical scales used for efficacy assessments.</p>
<p>For both the objectives, the data will be analysed overall and broken down by class of treatment (SSRI or atypical).</p>
</sec>
<sec id="sec2-0962280211432210"><title>2 Data</title>
<p>The basis for the analysis are the trials identified by the FDA for their analysis of suicide data.<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> Additional studies were identified from a subsequent meta-analysis<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> and through searching of online clinical trials registers of trials <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</ext-link> and results <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/">http://www.clinicalstudyresults.org/</ext-link> to identify trials undertaken after the FDA analysis. The search stopped on 6 June 2011. Where possible journal published results were obtained for the analysis. Since September 2007 in the USA, it has been compulsory to register all clinical trials.<sup><xref ref-type="bibr" rid="bibr15-0962280211432210">15</xref></sup> This legislation followed earlier legislation<sup><xref ref-type="bibr" rid="bibr16-0962280211432210">16</xref></sup> and regulatory<sup><xref ref-type="bibr" rid="bibr17-0962280211432210">17</xref></sup> and journal<sup><xref ref-type="bibr" rid="bibr18-0962280211432210">18</xref></sup> guidance, which in turn lead to an industry position on registration for all confirmatory trials initiated on or after 1 July 2005.<sup><xref ref-type="bibr" rid="bibr19-0962280211432210">19</xref></sup> Thus, although not a full proof search strategy, there is a narrow time window between the FDA analysis<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> and mandatory<sup><xref ref-type="bibr" rid="bibr17-0962280211432210">17</xref></sup> and voluntary<sup><xref ref-type="bibr" rid="bibr19-0962280211432210">19</xref></sup> registration as well as an interceding meta-analysis in 2007.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup></p>
<p>The background data for the analysis are given in <xref ref-type="table" rid="table8-0962280211432210">Table A3</xref>. For the purpose of the analysis in this article, the drugs Citalopram and Escatalopram will be separately reported – although they will be reported adjacent to each other in tables. Escitalopram is the S-enantiomer of the racemic mixture Citalopram.<sup><xref ref-type="bibr" rid="bibr20-0962280211432210">20</xref></sup>
</p>
<p>In this study, 35 trials are included in the analysis. There is one potentially additional completed trial in Paroxetine (NCT00708240) in Japanese children and adolescents (aged 7–17 years) for which no trial results were available.</p>
<p>The original data capture for the meta-analysis was done using Excel. The data were then transferred from Excel into SPSS and SAS for analysis.</p>
<sec id="sec3-0962280211432210"><title>2.1 Suicidal data</title>
<p>The suicidal data from the individual trials are given in <xref ref-type="table" rid="table6-0962280211432210">Table A1</xref>. For the 23 studies used in the FDA analysis, the FDA data are taken as the source.<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> This data set was then amended with four additional studies.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> Eight further studies (to make 35) are included in this analysis. For the 12 trials not in the original FDA analysis, the source for the data is given in <xref ref-type="table" rid="table6-0962280211432210">Table A1</xref>.
</p>
</sec>
<sec id="sec4-0962280211432210"><title>2.2 Efficacy data</title>
<p>The efficacy data from the individual trials are given in <xref ref-type="table" rid="table7-0962280211432210">Table A2</xref>. The full definitions of the endpoints used in the analysis are given in <xref ref-type="table" rid="table1-0962280211432210">Table 1</xref>.
<table-wrap id="table1-0962280211432210" position="float"><label>Table 1.</label><caption><p>Definitions of outcomes in the studies</p></caption>
<graphic alternate-form-of="table1-0962280211432210" xlink:href="10.1177_0962280211432210-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Abbreviation</th>
<th>Outcome</th>
</tr></thead>
<tbody align="left">
<tr>
<td>HAM-D</td>
<td>Hamilton Rating Scale for Depression</td>
</tr>
<tr>
<td>CDRS-R</td>
<td>Children’s Depression Rating Scale – Revised</td>
</tr>
<tr>
<td>CY-BOCS</td>
<td>Children’s Yale-Brown Obsessive Compulsive Disorder</td>
</tr>
<tr>
<td>MADRS</td>
<td>Montgomery Asperg Depression Rating Scale</td>
</tr>
<tr>
<td>CGI – global improvement</td>
<td>Clinical Global Impressions – global improvement</td>
</tr>
<tr>
<td>UCLA PTSD Index</td>
<td>UCLA Post Traumatic Stress Disorder Index</td>
</tr>
<tr>
<td>PARS</td>
<td>Paediatric Anxiety Rating Scale</td>
</tr>
<tr>
<td>SAS-CA</td>
<td>Social Anxiety Scale, Child or Adolescent Version</td>
</tr>
<tr>
<td>CGI</td>
<td>Clinical Global Impressions</td>
</tr>
<tr>
<td>K-SADS-P</td>
<td align="justify">Schedule for Affective Disorders and Schizophrenia for School Age Children– Present Episode Version</td>
</tr>
<tr>
<td>CPQ</td>
<td>Conners Parent Questionaire</td>
</tr>
<tr>
<td>C-KIDDIE SADS GAD</td>
<td align="justify">Columbia KIDDIE Schedule of Affective Disorders and Schizophrenia Sub-section GAD</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
<p>The studies for the efficacy data were grouped as per the FDA suicidal data given in <xref ref-type="table" rid="table7-0962280211432210">Table A2</xref>. Thus, although two Sertraline studies (1001 and 1017) were reported in a single paper, Wagner et al.,<sup><xref ref-type="bibr" rid="bibr21-0962280211432210">21</xref></sup> as were two Venlafaxine studies (382 and 394) in Emslie et al.<sup><xref ref-type="bibr" rid="bibr22-0962280211432210">22</xref></sup> and another two Venlafaxine studies (396 and 397) in Rynn et al.<sup><xref ref-type="bibr" rid="bibr23-0962280211432210">23</xref></sup> for the analysis in this article, they are kept as separate studies.</p>
<p>Consistency with the FDA analysis has also been maintained with other aspects. For example, for study CN104187 of Nefazodone, the FDA combined two doses of Nefazodone. The data in <xref ref-type="table" rid="table7-0962280211432210">Table A2</xref> are consistent with this, although this approach could be questioned. In addition for studies such as MH64089 of Sertraline, although other arms were included in the original trial, only the arms directly relevant to the meta-analysis are included here with the assumption that the other arms do not affect the arms of interest. This assumption could also be questioned.</p>
<p>The analysis is broken down by class of the drug (SSRI or atypical) and indication for the trial (depression or other indications). Again, this is consistent with the analysis of the FDA.</p>
<p><xref ref-type="table" rid="table7-0962280211432210">Table A2</xref> also highlights some additional features of the data. For five studies, Nefazodone (CN10411), Venlafaxine (382 and 394), Bupropion (45) and Escitalopram (SCT-MD-15), there was no information available as to the disposition of subjects in the intent to treat (ITT) population.</p>
<p>For one study, the standardised difference is calculated from a binary response, Fluoxetine (Birmaher). For two studies, the primary analysis as stated in the study of a dichotomised response was ignored: so a standardised difference could be derived from the original scale where the dichotomy was derived, Paroxetine (377 and 676).</p>
<p>For two trials, Escitalopram (SCT-MD-15 and SCT-MD-32), an estimate of the adjusted mean difference was available as were summary statistics for the treatment responses so the placebo response was taken from the summary statistics and the active response from the placebo response and the adjusted mean treatment difference.</p>
</sec>
</sec>
<sec id="sec5-0962280211432210"><title>3 Methods</title>
<sec id="sec6-0962280211432210"><title>3.1 Methodology for suicidal data</title>
<p>An important consideration in analysing the suicide data was the scale to be used to analyse the data. To undertake a meta-analysis, an average across all the studies is calculated where the contribution of each individual study to the average is proportional to the reciprocal of the standard error of the point estimate from an individual study. Hence, the smaller the standard error for an individual study, the greater the weight will be given to this study.</p>
<p>When applying a simple Normal approximation to calculate a standard error on the absolute risk difference scale, the standard error (for a given sample size) gets smaller as the number of events falls. Hence, greater weight is given to studies with fewest events. When working on a relative scale such as an odds ratio scale the opposite is true: the standard error gets bigger with fewer events and hence these studies are given less weight. In fact, the variance is relatively stable within the mean response range 0.3–0.7, but for the absolute risk difference falls quite markedly outside this range (and for the odds ratio, the variance increases).<sup><xref ref-type="bibr" rid="bibr24-0962280211432210">24</xref></sup> The data being analysed in this article are rare and so fall outside the range 0.3–0.7.</p>
<p>For the analysis of the suicide data, in this article, the absolute risk difference is used. This scale is chosen to allow easier interpretation of the risk increase in context with the baseline (placebo) risk. The primary analysis is, therefore, the absolute risk difference of active minus placebo. Hence, a positive sign indicates that active treatment has a higher observed absolute risk.</p>
<p>For the individual trials, instead of using simple Normal approximation, Wilson score confidence intervals are used. These are recommended for absolute risk differences.<sup><xref ref-type="bibr" rid="bibr25-0962280211432210">25</xref></sup> These confidence intervals are relatively simple to apply and give results broadly similar to more complex exact methods.<sup><xref ref-type="bibr" rid="bibr25-0962280211432210">25</xref></sup> Hence, for two observed absolute risks <italic>p<sub>A</sub></italic> and <italic>p<sub>B</sub></italic>, and for two different treatment groups A and B respectively, a Wilson score confidence interval which is the lower bound for confidence interval (L) for the risk difference, <inline-formula id="ilm1-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math1-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, is defined as<sup><xref ref-type="bibr" rid="bibr25-0962280211432210">25</xref></sup>
<disp-formula id="disp-formula1-0962280211432210"><label>(1)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math1-0962280211432210"><mml:mrow><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:math><graphic alternate-form-of="disp-formula1-0962280211432210" xlink:href="10.1177_0962280211432210-eq1.tif"/></disp-formula>
</p>
<p>while the upper bound is defined as
<disp-formula id="disp-formula2-0962280211432210"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math2-0962280211432210"><mml:mrow><mml:mi>U</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ɛ</mml:mi></mml:mrow></mml:math><graphic alternate-form-of="disp-formula2-0962280211432210" xlink:href="10.1177_0962280211432210-eq2.tif"/></disp-formula>
where <inline-formula id="ilm2-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math2-0962280211432210"><mml:mrow><mml:mi>δ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:msub><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm3-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math3-0962280211432210"><mml:mrow><mml:mi>ɛ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula>. Here, <italic>l<sub>A</sub></italic> and <italic>u<sub>A</sub></italic> are the lower and upper bounds for <italic>p<sub>A</sub></italic> and <italic>l<sub>B</sub></italic> and <italic>u<sub>B</sub></italic> the lower and upper bounds for <italic>p<sub>B</sub></italic>. These are obtained from the following for <italic>p<sub>A</sub></italic> and <italic>p<sub>B</sub></italic><sup><xref ref-type="bibr" rid="bibr25-0962280211432210">25</xref></sup>
<disp-formula id="disp-formula3-0962280211432210"><label>(3)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math3-0962280211432210"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>±</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic alternate-form-of="disp-formula3-0962280211432210" xlink:href="10.1177_0962280211432210-eq3.tif"/></disp-formula>
<disp-formula id="disp-formula4-0962280211432210"><label>(4)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math4-0962280211432210"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>±</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic alternate-form-of="disp-formula4-0962280211432210" xlink:href="10.1177_0962280211432210-eq4.tif"/></disp-formula>
</p>
<p>Wilson score method confidence intervals can be asymmetric for small sample sizes but become symmetric as the sample size increases.</p>
<p>This approach is a Normal approximation approach but calculates confidence intervals from zero event studies while also having confidence interval widths wider than the simple Normal approximation approach.</p>
<p>An initial analysis of the suicidal data across all the trials was undertaken using summary statistics based on simple aggregated counts. There are issues in doing such a naïve analysis but it is a good practice for such an analysis to be presented before performing a more detailed meta-analysis.</p>
<p>Overall estimates of effect were obtained from a random effects meta-analysis.<sup><xref ref-type="bibr" rid="bibr26-0962280211432210">26</xref></sup> Hence, the overall fixed effects estimate of θ, taken as the absolute risk difference across the studies is given by <inline-formula id="ilm4-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math4-0962280211432210"><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow></mml:math></inline-formula>,
<disp-formula id="disp-formula5-0962280211432210"><label>(5)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math5-0962280211432210"><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic alternate-form-of="disp-formula5-0962280211432210" xlink:href="10.1177_0962280211432210-eq5.tif"/></disp-formula>
</p>
<p>The random effects meta-analysis model allows each study to have its own parameter for the treatment effect, so that <inline-formula id="ilm5-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math5-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, follows a Normal distribution with mean <inline-formula id="ilm6-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math6-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. The parameter <inline-formula id="ilm7-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math7-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is assumed to follow a Normal distribution with mean θ and known variance <inline-formula id="ilm8-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math8-0962280211432210"><mml:mrow><mml:msup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, so that <inline-formula id="ilm9-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math9-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> now follows a Normal distribution with mean θ. The weights, <inline-formula id="ilm10-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math10-0962280211432210"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> in (5), are defined as <inline-formula id="ilm11-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math11-0962280211432210"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, where the <italic>w<sub>i</sub></italic> values for the meta-analysis are taken from the squared reciprocal of the Wilson score confidence interval widths of the individual trials (the width divided by 4). The between study variance <inline-formula id="ilm12-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math12-0962280211432210"><mml:mrow><mml:msup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is replaced by a suitable estimate <inline-formula id="ilm13-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math13-0962280211432210"><mml:mrow><mml:msup><mml:mrow><mml:mover><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, such as the methods of moments estimate given by Whitehead.<sup><xref ref-type="bibr" rid="bibr26-0962280211432210">26</xref></sup></p>
<p>Thus, using Wilson score confidence intervals, we can summarise both the results from all studies, including the studies with zero events, and use the confidence interval widths as weights for the meta-analysis.</p>
<p>With Wilson score confidence intervals, less weight is given to studies with fewer events in the meta-analysis compared to if a simple Normal approximation was used. To illustrate this point <xref ref-type="fig" rid="fig1-0962280211432210">Figure 1</xref> is provided. This figure is taken from a series of imagined trials. For each trial, there are 100 patients on each arm (of the two arm) trial. There is no difference between treatments such that the results are zero events on both arms; a single event on both arms, etc. <xref ref-type="fig" rid="fig1-0962280211432210">Figure 1(a)</xref> gives the precision, as assessed by the width of the confidence intervals, for various observed events from 0 to 20 for a Normal approximation and Wilson score confidence intervals. For 0 events for a simple Normal confidence interval, a half is added to both treatment arms.
<fig id="fig1-0962280211432210" position="float"><label>Figure 1.</label><caption><p>Plot of the confidence interval widths, weights and relative weights for the Wilson confidence intervals (dashed line) and simple Normal confidence intervals (solid line): (a) half-width of a confidence interval against observed number of events, (b) weight in a meta-analysis against number of events and (c) relative weight, compared to 20 observed number of events, against number of events.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig1.tif"/>
</fig></p>
<p>From <xref ref-type="fig" rid="fig1-0962280211432210">Figure 1(a)</xref>, it is apparent that: the widths of the confidence intervals are similar for 20 events on both treatment arms but the simple Normal confidence intervals become more narrow as the number of events decreases. This follows into <xref ref-type="fig" rid="fig1-0962280211432210">Figure 1(b)</xref> which demonstrates that the weight in a meta-analysis for trials with a small number of events have greater weight using the simple Normal confidence intervals. Using simple Normal approximation, therefore, from <xref ref-type="fig" rid="fig1-0962280211432210">Figure 1(c)</xref>, a study with zero events would have six times the weight a study with 20 events.</p>
<p>The primary endpoint is taken as that for suicidal behaviour or ideation. This is consistent with the FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> analysis. The analysis of the separate endpoints suicidal behaviour and suicidal ideation are taken as secondary. The primary analysis data set is taken as the data set with all trials in it including the zero event studies. The article will also undertake a meta-analysis with the zero event studies removed as a sensitivity analysis. The article also gives all the data use for the analysis so others can repeat the analysis undertaken.</p>
<p>Caution needs to be exercised when interpreting any effects for atypical therapies, here, as there are very comparatively few trials especially when breaking the results down. Therefore, any effect observed may actually be the effect of an individual compound rather than an overall effect for a class of compounds.</p>
<p>The results for the suicidal data are presented to three significant figures and to a maximum of five decimal places.</p>
</sec>
<sec id="sec7-0962280211432210"><title>3.2 Methodology for efficacy data</title>
<p>As highlighted in <xref ref-type="table" rid="table7-0962280211432210">Tables A2</xref> and <xref ref-type="table" rid="table1-0962280211432210">1</xref>, a number of scales were used to assess efficacy in the individual trials. An issue which became apparent was that different studies used different scales. This can be resolved by instead of using the mean difference <inline-formula id="ilm14-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math14-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> for individual trials – where <inline-formula id="ilm15-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math15-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm16-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math16-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the mean estimates of effect on treatments <italic>A</italic> and <italic>B</italic>, respectively – to instead use a scale independent standardised estimate of effect <inline-formula id="ilm17-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math17-0962280211432210"><mml:mrow><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula> – where <italic>s</italic> is a pooled estimate of the standard deviation. This standardised difference could be used to undertake a meta-analysis.<sup><xref ref-type="bibr" rid="bibr26-0962280211432210">26</xref></sup></p>
<p>A scale independent standardised difference was used for the analysis to assess efficacy.<sup><xref ref-type="bibr" rid="bibr26-0962280211432210">26</xref></sup> For this analysis, a negative sign indicates that active treatment has a higher treatment effect. The big assumption with a standardised difference, and with this analysis, is that the same standardised difference on this scale for the different outcomes has the same clinical meaning.</p>
<p>Summary statistics simply based on the observed effect size, independent of the size of the trial, were calculated.</p>
<p>Overall estimates of effect were obtained from a random effects meta-analysis.<sup><xref ref-type="bibr" rid="bibr26-0962280211432210">26</xref></sup> The overall estimate of effect will be interpreted from a point estimate and 95% confidence interval. The diagnostics will be as per the analysis of the suicidal data and the data will be similarly broken down.</p>
<p>Same caution needs to be observed when interpreting the effect of atypical therapies since few studies exist.</p>
<p>The results for the efficacy data are presented to three significant figures.</p>
</sec>
<sec id="sec8-0962280211432210"><title>3.3 Investigating heterogeneity</title>
<p>The usual test of homogeneity of the treatment effect across studies is based on the statistic
<disp-formula id="disp-formula6-0962280211432210"><label>(6)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math6-0962280211432210"><mml:mrow><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover><mml:msup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic alternate-form-of="disp-formula6-0962280211432210" xlink:href="10.1177_0962280211432210-eq6.tif"/></disp-formula>
</p>
<p>which is compared to a chi-squared distribution on <italic>k</italic> − 1 degrees of freedom. However, instead of doing a statistical test of the assumption of homogeneity, appropriate Normal probability plots will be inspected.<sup><xref ref-type="bibr" rid="bibr27-0962280211432210">27</xref></sup> These plots are derived from (6) such that the weighted residuals <italic>q<sub>i</sub></italic> from fitting a fixed effects meta-analysis are given by
<disp-formula id="disp-formula7-0962280211432210"><label>(7)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math7-0962280211432210"><mml:mrow><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow></mml:math><graphic alternate-form-of="disp-formula7-0962280211432210" xlink:href="10.1177_0962280211432210-eq7.tif"/></disp-formula>
</p>
<p>while under the standard fixed effects meta-analysis model, the standardised weighted residuals, <inline-formula id="ilm18-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math18-0962280211432210"><mml:mrow><mml:mi>q</mml:mi><mml:msub><mml:mrow><mml:mo>'</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, defined as<sup><xref ref-type="bibr" rid="bibr28-0962280211432210">28</xref></sup>
<disp-formula id="disp-formula8-0962280211432210"><label>(8)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math8-0962280211432210"><mml:mrow><mml:mi>q</mml:mi><mml:msub><mml:mrow><mml:mo>'</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic alternate-form-of="disp-formula8-0962280211432210" xlink:href="10.1177_0962280211432210-eq8.tif"/></disp-formula>
</p>
<p>would approximately follow a standard Normal distribution. Under the standard random effects meta-analysis, which is the primary analysis in this article, the weighted residuals and standardised weighted residuals would be calculated from <xref ref-type="disp-formula" rid="disp-formula6-0962280211432210">equations (6)</xref> and (<xref ref-type="disp-formula" rid="disp-formula8-0962280211432210">8</xref>) by replacing <italic>w<sub>i</sub></italic> and <inline-formula id="ilm19-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math19-0962280211432210"><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow></mml:math></inline-formula> with <inline-formula id="ilm20-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math20-0962280211432210"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm21-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math21-0962280211432210"><mml:mrow><mml:msup><mml:mrow><mml:mover><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, respectively.</p>
<p>A Normal probability plot of <inline-formula id="ilm22-0962280211432210"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math22-0962280211432210"><mml:mrow><mml:mi>q</mml:mi><mml:msub><mml:mrow><mml:mo>'</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> will thus be used to check the distributional assumptions of the meta-analysis model with confidence bands constructed under Normal approximation.<sup><xref ref-type="bibr" rid="bibr28-0962280211432210">28</xref></sup></p>
</sec>
</sec>
<sec id="sec9-0962280211432210"><title>4 Results</title>
<sec id="sec10-0962280211432210"><title>4.1 Background data</title>
<p>Data summarising individual trials are given in <xref ref-type="table" rid="table8-0962280211432210">Table A3</xref>. The data sources for this table are given in Tables A1 and A2. Not all data were from a regulatory (FDA or Medicines and Healthcare products Regulatory Agency (MHRA)) or peer reviewed source. A number of trials had information obtained from pharmaceutical company or trial registries.</p>
<p>There are 35 studies in the analysis of which 23 were in the original FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> analysis. Of the 23 in the original FDA analysis, 15 were trials for the indication of depression. Of the 12 other studies, 3 were trials for the indication of depression. All except 4 of the studies were undertaken wholly or in part in the USA with 18 of the studies for the indication of major depressive disorder. In the FDA investigation of the suicide-related events were blindly classified by a group of suicidology experts assembled by Columbia University.<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup> The data for the suicide events in the other 12 studies are obtained from journal articles (9 studies) or company reports (3 studies).</p>
<p>The earliest study was started in 1983 whilst the latest was 2003. For one study, the start date could not be determined.<sup><xref ref-type="bibr" rid="bibr29-0962280211432210">29</xref></sup> The average duration of the studies (in terms of treatment of patients) was 10.2 weeks ranging from 3 to 39 weeks. The average age of patients in the individual studies ranged from 8.49 to 16.11 years. For two studies, Fluoxetine (TADS)<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref>,<xref ref-type="bibr" rid="bibr30-0962280211432210">30</xref></sup> and Sertraline (Rynn),<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref>,<xref ref-type="bibr" rid="bibr29-0962280211432210">29</xref></sup> only the overall ages were available which have been put in <xref ref-type="table" rid="table8-0962280211432210">Table A3</xref> for each treatment group.</p>
<p>For two studies, recruitment was curtailed and the studies were stopped early by the sponsor with the results provided.<sup><xref ref-type="bibr" rid="bibr31-0962280211432210">31</xref>,<xref ref-type="bibr" rid="bibr32-0962280211432210">32</xref></sup></p>
</sec>
<sec id="sec11-0962280211432210"><title>4.2 Suicidal results</title>
<p>The data from the individual trials are given in <xref ref-type="table" rid="table6-0962280211432210">Table A1</xref>. <xref ref-type="table" rid="table9-0962280211432210">Table A4</xref> gives the data from Table A1 collapsed down by indication (depression and other indications) and therapy (SSRI or atypical). There is quite a range in the sample sizes in the sub groups while, for the primary endpoint, the proportion of subjects who have a suicidal behaviour or ideation is relatively low. From <xref ref-type="table" rid="table9-0962280211432210">Table A4</xref>, <xref ref-type="table" rid="table2-0962280211432210">Table 2</xref> is calculated by collapsing the table into overall totals. <xref ref-type="table" rid="table2-0962280211432210">Table 2</xref>, therefore, gives the absolute risk differences and 95% confidence intervals for the naively pooled analysis. The shaded boxes indicate analyses that are statistically significant – as indicated by a confidence interval excluding zero.
<table-wrap id="table2-0962280211432210" position="float"><label>Table 2.</label><caption><p>Overall suicidal behaviour, ideation and ideation and suicide results for SSRI and atypical treatments from a naïve analysis (absolute risk differences and 95% confidence intervals)</p></caption>
<graphic alternate-form-of="table2-0962280211432210" xlink:href="10.1177_0962280211432210-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th align="center" colspan="3">Indication</th>
</tr>
<tr><th>Depression</th>
<th>Other</th>
<th>Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><italic>Panel A: Suicidal behaviour</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00936 (−0.00093 to 0.01944)</td>
<td>0.00102 (−0.00544 to 0.00765)</td>
<td>0.00604 (−0.00051 to 0.01248)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.00158 (−0.00637 to 0.01091)</td>
<td>−0.00029 (−0.01549 to 0.01564)</td>
<td>0.00052 (−0.00566 to 0.00758)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00630 (−0.00095 to 0.01356)</td>
<td>0.00056 (−0.00492 to 0.00626)</td>
<td>0.00419 (−0.00059 0.00895)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel B: Suicidal ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00021 (−0.00974 to 0.01042)</td>
<td>0.00917 (−0.00034 to 0.01723)</td>
<td>0.00356 (−0.00326 to 0.01041)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01268 (0.00023 to 0.02373)</td>
<td>0.00542 (−0.00951 to 0.01792)</td>
<td>0.01000 (0.00152 to 0.01689)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00337 (−0.00421 to 0.01114)</td>
<td>0.00806 (0.00093 to 0.01394)</td>
<td>0.00530 (0.00012 to 0.01045)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel C: Suicidal behaviour or ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00958 (−0.00430 to 0.02348)</td>
<td>0.01019 (−0.00006 to 0.01926)</td>
<td>0.00960 (0.00040 to 0.01877)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01426 (0.00135 to 0.02560)</td>
<td>0.00513 (−0.01243 to 0.02187)</td>
<td>0.01052 (0.00117 to 0.01915)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00967 (−0.00055 to 0.02000)</td>
<td>0.00862 (0.00044 to 0.01608)</td>
<td>0.00949 (0.00261 to 0.01636)</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
<p>There is an issue in such an analysis as naive pooling can produce contradictory answers – showing that a treatment has an effect in one direction when a meta-analysis demonstrates that the difference is in the opposite direction.<sup><xref ref-type="bibr" rid="bibr33-0962280211432210">33</xref>,<xref ref-type="bibr" rid="bibr34-0962280211432210">34</xref></sup> This phenomenon is known as Simpson’s Paradox.<sup><xref ref-type="bibr" rid="bibr35-0962280211432210">35</xref></sup> In a meta-analysis, such a problem can occur when there is imbalance in the allocation to treatment.<sup><xref ref-type="bibr" rid="bibr33-0962280211432210">33</xref></sup> There is imbalance in four of the studies being investigated here (<xref ref-type="table" rid="table6-0962280211432210">Table A1</xref>).</p>
<p>However, a descriptive analysis can be an interesting first analysis to undertake before performing a full meta-analysis. Consistency of results will give assurance as to interpretation. Conversely, contradictory results would flag the need for further investigation.</p>
<p>A meta-analysis of the data are given in <xref ref-type="table" rid="table3-0962280211432210">Table 3</xref> and <xref ref-type="fig" rid="fig2-0962280211432210">Figure 2</xref>. The appendix has supporting results by compound in <xref ref-type="table" rid="table10-0962280211432210">Table A5</xref> and overall but omitting studied with no events in <xref ref-type="table" rid="table11-0962280211432210">Table A6</xref>.
<table-wrap id="table3-0962280211432210" position="float"><label>Table 3.</label><caption><p>Overall suicidal behaviour, ideation and ideation and suicide results for SSRI and atypical treatments from a meta-analysis (absolute risk differences and 95% confidence intervals)</p></caption>
<graphic alternate-form-of="table3-0962280211432210" xlink:href="10.1177_0962280211432210-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th align="center" colspan="3">Indication</th>
</tr>
<tr><th>Depression</th>
<th>Other</th>
<th>Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><italic>Panel A: Suicidal behaviour</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00816 (−0.00565 to 0.02196)</td>
<td>−0.00086 (−0.01654 to 0.01482)</td>
<td>0.00422 (−0.00614 to 0.01458)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.00155 (−0.01649 to 0.01959)</td>
<td>0.00030 (−0.02382 to 0.02442)</td>
<td>0.00110 (−0.01335 to 0.01555)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00572 (−0.00525 to 0.01668)</td>
<td>−0.00052 (−0.01366 to 0.01263)</td>
<td>0.00316 (−0.00526 to 0.01158)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel B: Suicidal ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>−0.00011 (−0.01310 to 0.01289)</td>
<td>0.00937 (−0.00775 to 0.02649)</td>
<td>0.00336 (−0.00699 to 0.01371)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01014 (−0.00903 to 0.02931)</td>
<td>0.00705 (−0.01657 to 0.03067)</td>
<td>0.00891 (−0.00597 to 0.02380)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00312 (−0.00764 to 0.01387)</td>
<td>0.00857 (−0.00529 to 0.02243)</td>
<td>0.00517 (−0.00333 to 0.01366)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel C: Suicidal behaviour or ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00844 (−0.00752 to 0.02439)</td>
<td>0.00859 (−0.00878 to 0.02595)</td>
<td>0.00850 (−0.00324 to 0.02025)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01095 (−0.00833 to 0.03022)</td>
<td>0.00683 (−0.01881 to 0.03247)</td>
<td>0.00946 (−0.00595 to 0.02487)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00946 (−0.00283 to 0.02175)</td>
<td>0.00803 (−0.00635 to 0.02240)</td>
<td>0.00886 (−0.00049 to 0.01820)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig2-0962280211432210" position="float"><label>Figure 2.</label><caption><p>Suicidal behaviour results for individual trials by suicidal outcome: (a) behaviour, (b) ideation and (c) behaviour or ideation.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig2.tif"/>
</fig>
</p>

<p><xref ref-type="fig" rid="fig2-0962280211432210">Figure 2</xref> gives the point estimate (of the absolute risk difference) and confidence interval from the meta-analysis for each study for suicidal behaviour (<xref ref-type="fig" rid="fig2-0962280211432210">Figure 2a</xref>), suicidal ideation (<xref ref-type="fig" rid="fig2-0962280211432210">Figure 2b</xref>) and suicidal behaviour or ideation (<xref ref-type="fig" rid="fig2-0962280211432210">Figure 2c</xref>). For suicidal behaviour, the point estimates tend to be very close to zero, for suicidal ideation, there does seem to be more noise in the absolute risk difference which is in turn reflected in suicidal behaviour or ideation.</p>
<p>The overall absolute risk excess for suicidal behaviour or ideation is 0.00886 (95% CI −0.00049 to 0.02820). Hence, the excess risk compared to placebo is that 9 in 1000 patients will have suicidal behaviour or ideation although this could be as low as 5 in 10 000 in favour of treatment (i.e. there is less risk compared to placebo) or as high as 28 in 1000.</p>
<p>As a sensitivity analysis, the meta-analysis was repeated excluding studies which observed no events on either treatment arm. The results are presented in <xref ref-type="table" rid="table11-0962280211432210">Table A6</xref>. Removing these studies has the effect of increasing the estimates of absolute risk excess compared to the estimates from <xref ref-type="table" rid="table3-0962280211432210">Table 3</xref>. The overall absolute risk excess for suicidal behaviour or ideation is now 0.01120 (95% CI 0.00069 to 0.02170. Hence, the excess risk compared to placebo is that 11 in 1000 patients will have suicidal behaviour or ideation although this could be as low as 7 in 10 000 or as high as 22 in 1000. The difference is now statistically significant. It should be noted though that removal of studies with zero events has the effect of removing some studies that support the statistical null hypothesis – of no risk difference between treatments.</p>
<p>An investigation of the heterogeneity through visual inspection of the diagnostic plots of the standardised residuals is shown in Figures <xref ref-type="fig" rid="fig3-0962280211432210">3</xref> and <xref ref-type="fig" rid="fig4-0962280211432210">4</xref>. <xref ref-type="fig" rid="fig3-0962280211432210">Figure 3</xref> illustrates a histogram of the residuals. There seems to be no great deviation from the assumption that the residuals are sampled from a Normal distribution. However, the summary statistics seem to indicate that the variance is less than 1 and so the assumption that the residuals are standard Normal may not hold. This is confirmed in <xref ref-type="fig" rid="fig4-0962280211432210">Figure 4</xref> which are Normal probability plots of the observed standardised residuals against a standardised Normal.
<fig id="fig3-0962280211432210" position="float"><label>Figure 3.</label><caption><p>Histograms of standardised residuals for suicidal behaviour results by suicidal outcome: (a) behaviour, (b) ideation and (c) behaviour or ideation.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig3.tif"/>
</fig>
<fig id="fig4-0962280211432210" position="float"><label>Figure 4.</label><caption><p>Normal probability plots of standardised residuals for suicidal behaviour results by suicidal outcome: (a) behaviour, (b) ideation and (c) behaviour or ideation.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig4.tif"/>
</fig></p>
<p>In a data-dependent analysis, a sensitivity analysis was undertaken with the results given in the appendix. For suicidal behaviour, the weights for the meta-analysis were based on the confidence interval divided by 8, while for ideation and behaviour or ideation, the weights analyses were based on the confidence interval divided by 6. The results from the amended analysis are given in <xref ref-type="fig" rid="fig8-0962280211432210">Figure A1</xref> and <xref ref-type="table" rid="table12-0962280211432210">Table A7</xref>.</p>
<p><xref ref-type="fig" rid="fig8-0962280211432210">Figure A1</xref> gives the Normal probability plots for the analyses with the amended weights. Deviations from the assumptions of standard Normal distribution for the standardised residuals for the analyses seem to be less pronounced now. For primary endpoint of suicidal behaviour or ideation, there seems to be least deviation from the standard Normal assumption.</p>
<p><xref ref-type="table" rid="table12-0962280211432210">Table A7</xref> gives the results from the data-dependent analysis with the amended weights. The results seem to be consistent with <xref ref-type="table" rid="table2-0962280211432210">Table 2</xref> in terms of the point estimates of effect. The errors for the point estimates are now smaller, however, meaning more narrow confidence intervals and more results which are statistically significant.</p>
<p>The results from <xref ref-type="table" rid="table2-0962280211432210">Table 2</xref> remain the primary analysis.</p>
</sec>
<sec id="sec12-0962280211432210"><title>4.3 Efficacy results</title>
<p>The data from the individual trials are given in the appendix <xref ref-type="table" rid="table7-0962280211432210">TableA2</xref>.</p>
<p><xref ref-type="table" rid="table4-0962280211432210">Table 4</xref> gives the data from <xref ref-type="table" rid="table7-0962280211432210">Table A2</xref> collapsed down by indication and therapy. This analysis simply summarises the standardised differences from the individual studies ignoring the actual size of the studies. Overall, the estimate of effect in terms of a standardised difference is −0.33 (against placebo). The maximum estimate of effect is −1.56 against placebo, while the maximum effect in favour of placebo is 0.24.
<table-wrap id="table4-0962280211432210" position="float"><label>Table 4.</label><caption><p>Efficacy results for individual compounds for SSRI and atypical treatments (standardised mean differences)</p></caption>
<graphic alternate-form-of="table4-0962280211432210" xlink:href="10.1177_0962280211432210-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="2"/><th>Count</th>
<th>Minimum</th>
<th>Mean</th>
<th>Maximum</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="3">SSRI</td>
<td>Depression</td>
<td>13</td>
<td>−0.66</td>
<td>−0.25</td>
<td>0.06</td>
</tr>
<tr>
<td>Other</td>
<td>13</td>
<td>−1.56</td>
<td>−0.47</td>
<td>0.24</td>
</tr>
<tr>
<td>Group total</td>
<td>26</td>
<td>−1.56</td>
<td>−0.36</td>
<td>0.24</td>
</tr>
<tr>
<td rowspan="3">Atypical</td>
<td>Depression</td>
<td>5</td>
<td>−0.26</td>
<td>−0.15</td>
<td>−0.03</td>
</tr>
<tr>
<td>Other</td>
<td>4</td>
<td>−0.61</td>
<td>−0.39</td>
<td>−0.15</td>
</tr>
<tr>
<td>Group total</td>
<td>9</td>
<td>−0.61</td>
<td>−0.26</td>
<td>−0.03</td>
</tr>
<tr>
<td>Table total</td>
<td>35</td>
<td>−1.56</td>
<td>−0.33</td>
<td>0.24</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
<p>A meta-analysis of the data are given in <xref ref-type="table" rid="table5-0962280211432210">Table 5</xref> as well as in <xref ref-type="fig" rid="fig5-0962280211432210">Figure 5</xref>. <xref ref-type="fig" rid="fig5-0962280211432210">Figure 5</xref> gives the point estimate (of the standardised difference) and confidence interval from the meta-analysis for each study. From inspection of this figure, there does seem to be a wide range of effects in the trials.
<table-wrap id="table5-0962280211432210" position="float"><label>Table 5.</label><caption><p>Overall efficacy results for SSRI and atypical treatments (standardised mean differences and 95% confidence intervals)</p></caption>
<graphic alternate-form-of="table5-0962280211432210" xlink:href="10.1177_0962280211432210-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th align="center" colspan="3">Indication</th>
</tr>
<tr><th>Depression</th>
<th>Other</th>
<th>Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td>SSRI</td>
<td>−0.24 (−0.35 to −0.13)</td>
<td>−0.48 (−0.68 to −0.27)</td>
<td>−0.34 (−0.46 to −0.23)</td>
</tr>
<tr>
<td>Atypical</td>
<td>−0.15 (−0.27 to −0.02)</td>
<td>−0.43 (−0.61 to −0.25)</td>
<td>−0.26 (−0.39 to −0.13)</td>
</tr>
<tr>
<td>Overall</td>
<td>−0.21 (−0.30 to −0.13)</td>
<td>−0.45 (−0.61 to −0.30)</td>
<td>−0.32 (−0.41 to −0.23)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig5-0962280211432210" position="float"><label>Figure 5.</label><caption><p>Overall efficacy results.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig5.tif"/>
</fig>
</p>
<p>A further consideration is constancy of effect over time. A previous investigation had shown a correlation between treatment effect (the effect of active over placebo) and time of 0.28 in clinical trial in a depression population.<sup><xref ref-type="bibr" rid="bibr36-0962280211432210">36</xref></sup> In this investigation, the weighted correlation (weighting on the sample size in the individual studies) is 0.04. Hence, the assumption of constancy of effect with time seems reasonable.</p>
<p><xref ref-type="table" rid="table13-0962280211432210">Table A8</xref> gives meta-analyses for the individual compounds. There seems to be a wide variation in the effects observed between compounds for trials to assess both the effect in depression than for other indications.</p>
<p>From <xref ref-type="table" rid="table5-0962280211432210">Table 5</xref>, the overall estimate of effect is −0.32 (95% CI of −0.41 to −0.23) of a standardised difference in favour of active treatment. As this is measured on a standardised difference scale, we can consider its interpretation in context with a standard deviation. Suppose the scale of interest is the Hamilton Rating Scale for Depression, and we expect a standard deviation of approximately 8 on this scale, a standardised difference of −0.32 could be interpreted as a mean reduction of 2.5.</p>
<p>Something to highlight is that it seems that SSRI studies conducted to investigate the effect for depression seem to have smaller effects than studies in other indications. Thus, the overall effect for SSRIs for the indication of depression is −0.24 (95% CI −0.35 to −0.13). This is around 25% less than the overall effect.</p>
<p>An investigation of the heterogeneity through visual inspection of the diagnostic plots of the standardised residuals is given in Figures <xref ref-type="fig" rid="fig6-0962280211432210">6</xref> and <xref ref-type="fig" rid="fig7-0962280211432210">7</xref>. <xref ref-type="fig" rid="fig6-0962280211432210">Figure 6</xref> gives a histogram of the residuals. There seems to be no great deviation from the assumption that the residuals are sampled from a standard Normal distribution. This is confirmed in <xref ref-type="fig" rid="fig7-0962280211432210">Figure 7</xref>, which shows the Normal probability plots of the observed standardised residuals against a standardised Normal.
<fig id="fig6-0962280211432210" position="float"><label>Figure 6.</label><caption><p>Histograms of standardised residuals for the efficacy results.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig6.tif"/></fig>
<fig id="fig7-0962280211432210" position="float"><label>Figure 7.</label><caption><p>Normal probability plots of standardised residuals for the efficacy results.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig7.tif"/>
</fig></p>
<p>There is one apparent outlying study from <xref ref-type="fig" rid="fig7-0962280211432210">Figure 7</xref> – a study that is outside the confidence bands. The one outlying study in the analysis investigating Sertraline for the treatment of Generalised Anxiety Disorder.<sup><xref ref-type="bibr" rid="bibr37-0962280211432210">37</xref></sup> This had a standardised effect of −1.56 in a study with 56 patients in total. In <xref ref-type="table" rid="table14-0962280211432210">Table A9</xref>, results of a sensitivity analysis for the meta-analysis with the outlying study removed are given. The results are consistent with the results in <xref ref-type="table" rid="table5-0962280211432210">Table 5</xref> and so these remain the primary analysis.</p>
</sec>
</sec>
<sec id="sec13-0962280211432210" sec-type="discussions"><title>5 Discussion</title>
<p>The data for the meta-analysis presented a number of potential problems. First for the investigation of heterogeneity for both efficacy and suicidal data, it was highlighted how diagnostic plots, sensitivity analyses and summary statistics can assist in the interpretation of results.</p>
<p>The suicidal data presented the additional problem of the events of interest being rare. An analysis was described in the article to account for the rare events that also included studies which had no events on either treatment arm.</p>
<p>The meta-analysis in the article was of 35 studies and it was demonstrated that antidepressants have statistically significant effects in terms of efficacy. These effects were less in trials investigating the indication of depression than trials investigating other indications. Overall, the standardised mean difference was −0.32 (95% CI −0.41 to −0.23) in favour of active.</p>
<p>With respect to the analysis of suicidal data, the trends were against active treatment with an absolute risk increase of 0.00886 (95% CI of −0.00049 to 0.0182) of active against placebo for suicidal behaviour or ideation. Hence, the excess risk against placebo is 9 in 1000 more patients who will have suicidal behaviour or ideation. This risk seemed to be constant within sub-groups. Hence, the risk of suicidal behaviour or ideation seems to remain constant across indication, while the benefit of treatment seems to vary by indication.</p>
<p>The meta-analysis in this article is consistent with the results of previously reported meta-analyses of efficacy data.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref>–<xref ref-type="bibr" rid="bibr14-0962280211432210">14</xref></sup> For example, in an analysis of 27 trials Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> reported for suicidal behaviour or ideation a risk difference of 0.007 for major compared to 0.009 in this study. While for the indication of major depression, the same authors reported a standardised difference of −0.20 compared to −0.21 in this study.</p>
<p>The updated results in this article lend to the discussions on SSRIs by updating the data used in previous analyses for both the assessment of efficacy and suicidal behaviour. It is recommended that the approaches described to investigate heterogeneity should be used for all meta-analyses.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>Steven A Julious currently consults to the pharmaceutical industry for which his University receives payment and he indirectly benefits, and he gives courses from which he directly benefits.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0962280211432210"><label>1</label><citation citation-type="other"><comment>FDA. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf">http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr2-0962280211432210"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammad</surname><given-names>TA</given-names></name><name><surname>Laughren</surname><given-names>T</given-names></name><name><surname>Racoosin</surname><given-names>J</given-names></name></person-group>. <article-title>Suicidality in pediatric patients treated with antidepressant drugs</article-title>. <source>Arch Gen Psychiatry</source> <year>2006</year>; <volume>63</volume>: <fpage>246</fpage>–<lpage>248</lpage>.</citation></ref>
<ref id="bibr3-0962280211432210"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaizar</surname><given-names>EE</given-names></name><name><surname>Greenhousea</surname><given-names>JB</given-names></name><name><surname>Seltmana</surname><given-names>H</given-names></name><name><surname>Kelleherc</surname><given-names>K</given-names></name></person-group>. <article-title>Do antidepressants cause suicidality in children? A Bayesian meta-analysis</article-title>. <source>Clin Trials</source> <year>2006</year>; <volume>3</volume>: <fpage>73</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr4-0962280211432210"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AH</given-names></name><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Mayes</surname><given-names>TL</given-names></name></person-group>. <article-title>Review of the efficacy and safety of antidepressants in youth depression</article-title>. <source>J Child Psychol Psychiatry</source> <year>2005</year>; <volume>46</volume>(<issue>7</issue>): <fpage>735</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr5-0962280211432210"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AH</given-names></name><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Mayes</surname><given-names>TL</given-names></name></person-group>. <article-title>The use of antidepressants to treat depression in children and adolescents</article-title>. <source>CMAJ</source> <year>2006</year>; <volume>174</volume>(<issue>2</issue>): <fpage>193</fpage>–<lpage>200</lpage>.</citation></ref>
<ref id="bibr6-0962280211432210"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whittington</surname><given-names>CJ</given-names></name><name><surname>Kendall</surname><given-names>T</given-names></name><name><surname>Fonagy</surname><given-names>P</given-names></name><name><surname>Cottrell</surname><given-names>D</given-names></name><name><surname>Cotgrove</surname><given-names>A</given-names></name><name><surname>Boddington</surname><given-names>E</given-names></name></person-group>. <article-title>Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data</article-title>. <source>Lancet</source> <year>2004</year>; <volume>363</volume>: <fpage>1341</fpage>–<lpage>1345</lpage>.</citation></ref>
<ref id="bibr7-0962280211432210"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jick</surname><given-names>H</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Jick</surname><given-names>SS</given-names></name></person-group>. <article-title>Antidepressants and the risk of suicidal behaviors</article-title>. <source>JAMA</source> <year>2004</year>; <volume>292</volume>: <fpage>338</fpage>–<lpage>343</lpage>.</citation></ref>
<ref id="bibr8-0962280211432210"><label>8</label><citation citation-type="other"><comment>FDA. Revisions to product labeling, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf">http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr9-0962280211432210"><label>9</label><citation citation-type="other"><comment>Committee on the Safety of Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants, <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf">http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr10-0962280211432210"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunnell</surname><given-names>D</given-names></name><name><surname>Saperia</surname><given-names>J</given-names></name><name><surname>Ashby</surname><given-names>D</given-names></name></person-group>. <article-title>Selective Serotonin Reuptake Inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review</article-title>. <source>BMJ</source> <year>2005</year>; <volume>330</volume>: <fpage>385</fpage>–<lpage>385</lpage>.</citation></ref>
<ref id="bibr11-0962280211432210"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Rietbrock</surname><given-names>S</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Ashby</surname><given-names>D</given-names></name><name><surname>Chick</surname><given-names>J</given-names></name><name><surname>Moseley</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study</article-title>. <source>BMJ</source> <year>2005</year>; <volume>330</volume>: <fpage>389</fpage>–<lpage>393</lpage>.</citation></ref>
<ref id="bibr12-0962280211432210"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>JA</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Salary</surname><given-names>CB</given-names></name><name><surname>Barbe</surname><given-names>RP</given-names></name><name><surname>Birmaher</surname><given-names>B</given-names></name><name><surname>Pincus</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials</article-title>. <source>JAMA</source> <year>2007</year>; <volume>297</volume>: <fpage>1683</fpage>–<lpage>1696</lpage>.</citation></ref>
<ref id="bibr13-0962280211432210"><label>13</label><citation citation-type="other"><comment>Hazell P, O’Connell D, Heathcote D and Henry DA. Tricyclic drugs for depression in children and adolescents (Review). <italic>Cochrane Database Syst Rev</italic> 2002; (2): Art. No.: CD002317. DOI: 10.1002/14651858.CD002317</comment>.</citation></ref>
<ref id="bibr14-0962280211432210"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsapakis</surname><given-names>EM</given-names></name><name><surname>Soldani</surname><given-names>F</given-names></name><name><surname>Tondo</surname><given-names>L</given-names></name><name><surname>Baldessarin</surname><given-names>RJ</given-names></name></person-group>. <article-title>Efficacy of antidepressants in juvenile depression: meta-analysis</article-title>. <source>Br J Psychiatry</source> <year>2008</year>; <volume>193</volume>: <fpage>10</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr15-0962280211432210"><label>15</label><citation citation-type="other"><comment>110th US Congress. Public Law 110-85, <ext-link ext-link-type="uri" xlink:href="http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&amp;docid=f:publ085.110">http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&amp;docid=f:publ085.110</ext-link> (2007, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr16-0962280211432210"><label>16</label><citation citation-type="other"><comment>Food and Drug Administration. Food and Drug Administration Modernization Act (FDAMA) of 1997, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/default.htm">http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/default.htm</ext-link> (1997, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr17-0962280211432210"><label>17</label><citation citation-type="other"><comment>FDA/Center for Drug Evaluation and Research. Guidance for industry information program on clinical trials for serious or life-threatening diseases and conditions, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126838.pdf">http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126838.pdf</ext-link> (2002, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr18-0962280211432210"><label>18</label><citation citation-type="journal"><collab>International Committee of Medical Journal Editors</collab>. <article-title>Uniform requirements for manuscripts submitted to biomedical journals</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>911</fpage>–<lpage>912</lpage>.</citation></ref>
<ref id="bibr19-0962280211432210"><label>19</label><citation citation-type="other"><comment>IFPMA. Joint position on the disclosure of clinical trial information via clinical trial registries and databases, updated November 2008, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.ifpma.org/fileadmin/files/pdfs/EN/Revised_Joint_Industry_Position_Nov_2008.pdf">http://clinicaltrials.ifpma.org/fileadmin/files/pdfs/EN/Revised_Joint_Industry_Position_Nov_2008.pdf</ext-link> (2008, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr20-0962280211432210"><label>20</label><citation citation-type="other"><comment>UKMi. Evaluated information for the NHS: escitalopram, <ext-link ext-link-type="uri" xlink:href="http://www.ukmi.nhs.uk/NewMaterial/html/docs/escitalopram.pdf">http://www.ukmi.nhs.uk/NewMaterial/html/docs/escitalopram.pdf</ext-link> (2002, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr21-0962280211432210"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Ambrosini</surname><given-names>P</given-names></name><name><surname>Rynn</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials</article-title>. <source>JAMA</source> <year>2003</year>; <volume>290</volume>: <fpage>1033</fpage>–<lpage>1041</lpage>.</citation></ref>
<ref id="bibr22-0962280211432210"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Yeung</surname><given-names>PP</given-names></name><name><surname>Kunz</surname><given-names>NR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>Venlafaxine ER for the treatment of pediatric subjects with depression: results of 2 placebo-controlled trials</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2007</year>; <volume>46</volume>: <fpage>479</fpage>–<lpage>488</lpage>.</citation></ref>
<ref id="bibr23-0962280211432210"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rynn</surname><given-names>MA</given-names></name><name><surname>Riddle</surname><given-names>MA</given-names></name><name><surname>Yeung</surname><given-names>PP</given-names></name><name><surname>Kunz</surname><given-names>NR</given-names></name></person-group>. <article-title>Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials</article-title>. <source>Am J Psychiatry</source> <year>2007</year>; <volume>164</volume>: <fpage>290</fpage>–<lpage>300</lpage>.</citation></ref>
<ref id="bibr24-0962280211432210"><label>24</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name></person-group>. <source>Sample sizes for clinical trials</source>, <publisher-loc>London, England</publisher-loc>: <publisher-name>Chapman and Hall</publisher-name>, <year>2010</year>.</citation></ref>
<ref id="bibr25-0962280211432210"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newcombe</surname><given-names>RG</given-names></name></person-group>. <article-title>Interval estimation for the difference between independent proportions: comparison of eleven methods</article-title>. <source>Stat Med</source> <year>1998</year>; <volume>17</volume>: <fpage>873</fpage>–<lpage>890</lpage>.</citation></ref>
<ref id="bibr26-0962280211432210"><label>26</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>A</given-names></name></person-group>. <source>Meta-analysis of controlled clinical trials</source>, <publisher-loc>Chichester</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2002</year>.</citation></ref>
<ref id="bibr27-0962280211432210"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>RF</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Detecting and describing heterogeneity in meta analysis</article-title>. <source>Stat Med</source> <year>1998</year>; <volume>17</volume>: <fpage>841</fpage>–<lpage>856</lpage>.</citation></ref>
<ref id="bibr28-0962280211432210"><label>28</label><citation citation-type="other"><comment>Julious SA and Whitehead A. Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis. <italic>Pharm Stat</italic> DOI: 10.1002/pst.494</comment>.</citation></ref>
<ref id="bibr29-0962280211432210"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rynn</surname><given-names>MA</given-names></name><name><surname>Siqueland</surname><given-names>L</given-names></name><name><surname>Rickels</surname><given-names>K</given-names></name></person-group>. <article-title>Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder</article-title>. <source>Am J Psychiatry</source> <year>2001</year>; <volume>158</volume>: <fpage>2008</fpage>–<lpage>2014</lpage>.</citation></ref>
<ref id="bibr30-0962280211432210"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>March</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>S</given-names></name><name><surname>Petrycki</surname><given-names>S</given-names></name><name><surname>Curry</surname><given-names>J</given-names></name><name><surname>Wells</surname><given-names>K</given-names></name><name><surname>Fairbank</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Treatment for Adolescents With Depression Study (TADS) Team</article-title>. <source><italic>Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial</italic>. JAMA</source> <year>2004</year>; <volume>292</volume>: <fpage>807</fpage>–<lpage>820</lpage>.</citation></ref>
<ref id="bibr31-0962280211432210"><label>31</label><citation citation-type="other"><comment>Pfizer. A multicenter, 10-week, randomized, double-blind study of sertraline and placebo in children and adolescents with Posttraumatic Stress Disorder (PTSD), <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_2909_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_2909_0.pdf</ext-link> (2008, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr32-0962280211432210"><label>32</label><citation citation-type="other"><comment>Pfizer. Sertraline in the treatment of Obsessive Compulsive Disorder (OCD), <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_1595_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_1595_0.pdf</ext-link> (2006, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr33-0962280211432210"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chuang-Stein</surname><given-names>C</given-names></name><name><surname>Beltangady</surname><given-names>M</given-names></name></person-group>. <article-title>Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies</article-title>. <source>Pharm Stat</source> <year>2011</year>; <volume>10</volume>(<issue>1</issue>): <fpage>3</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr34-0962280211432210"><label>34</label><citation citation-type="other"><comment>Rucker G and Schumacher M. Simpson’s Paradox visualized: the example of the Rosiglitazone meta-analysis. <italic>BMC Med Res Methodol</italic> 2008; <bold>8</bold>: 34. <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2288/8/34">http://www.biomedcentral.com/1471-2288/8/34</ext-link> (2008, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr35-0962280211432210"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Mullee</surname><given-names>MA</given-names></name></person-group>. <article-title>Confounding and Simpson’s Paradox</article-title>. <source>Br Med J</source> <year>1994</year>; <volume>309</volume>(<issue>6967</issue>): <fpage>1480</fpage>–<lpage>1481</lpage>.</citation></ref>
<ref id="bibr36-0962280211432210"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name></person-group>. <article-title>Issues with indirect comparisons in clinical trials particularly with respect to non-inferiority trials</article-title>. <source>Drug Inf J</source> <year>2008</year>; <volume>42</volume>(<issue>6</issue>): <fpage>625</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr37-0962280211432210"><label>37</label><citation citation-type="journal"><collab>POTS</collab>. <article-title>The Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial</article-title>. <source>JAMA</source> <year>2004</year>; <volume>292</volume>: <fpage>1969</fpage>–<lpage>1976</lpage>.</citation></ref>
<ref id="bibr38-0962280211432210"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liebowitz</surname><given-names>MR</given-names></name><name><surname>Turner</surname><given-names>SM</given-names></name><name><surname>Piacentini</surname><given-names>J</given-names></name><name><surname>Beidel</surname><given-names>DC</given-names></name><name><surname>Clarvit</surname><given-names>SR</given-names></name><name><surname>Davies</surname><given-names>SO</given-names></name><etal/></person-group>. <article-title>Fluoxetine in children and adolescents with OC: a placebo-controlled trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2002</year>; <volume>41</volume>: <fpage>1431</fpage>–<lpage>1438</lpage>.</citation></ref>
<ref id="bibr39-0962280211432210"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birmaher</surname><given-names>B</given-names></name><name><surname>Axelson</surname><given-names>DA</given-names></name><name><surname>Monk</surname><given-names>K</given-names></name><name><surname>Kalas</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>DB</given-names></name><name><surname>Ehmann</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Fluoxetine for the treatment of childhood anxiety disorders</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2003</year>; <volume>42</volume>: <fpage>415</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr40-0962280211432210"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walkup</surname><given-names>JT</given-names></name><name><surname>Albano</surname><given-names>AM</given-names></name><name><surname>Piacentini</surname><given-names>J</given-names></name><name><surname>Birmaher</surname><given-names>B</given-names></name><name><surname>Compton</surname><given-names>SN</given-names></name><name><surname>Sherrill</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>359</volume>(<issue>26</issue>): <fpage>2753</fpage>–<lpage>2766</lpage>.</citation></ref>
<ref id="bibr41-0962280211432210"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>RUPP</surname></name></person-group>. <article-title>Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents</article-title>. <source>N Engl J Med</source> <year>2001</year>; <volume>344</volume>: <fpage>1279</fpage>–<lpage>1285</lpage>.</citation></ref>
<ref id="bibr42-0962280211432210"><label>42</label><citation citation-type="other"><comment>Forest. A double blind placebo controlled evaluation of the safety and efficacy of escitalopram in pediatric depression, <ext-link ext-link-type="uri" xlink:href="http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-15_final.pdf">http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-15_final.pdf</ext-link> (2008, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr43-0962280211432210"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Jonas</surname><given-names>J</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Ventura</surname><given-names>D</given-names></name><name><surname>Saikali</surname><given-names>K</given-names></name></person-group>. <article-title>A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2006</year>; <volume>45</volume>: <fpage>280</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr44-0962280211432210"><label>44</label><citation citation-type="other"><comment>Forest. A double blind flexible dose study of escitalopram in pediatric with major depressive disorder, <ext-link ext-link-type="uri" xlink:href="http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-32_final.pdf">http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-32_final.pdf</ext-link> (2005, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr45-0962280211432210"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>March</surname><given-names>JS</given-names></name><name><surname>Entsuah</surname><given-names>AR</given-names></name><name><surname>Rynn</surname><given-names>M</given-names></name><name><surname>Albano</surname><given-names>AM</given-names></name><name><surname>Tourian</surname><given-names>KA</given-names></name></person-group>. <article-title>A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder</article-title>. <source>Biol Psychiatry</source> <year>2007</year>; <volume>62</volume>: <fpage>1149</fpage>–<lpage>1154</lpage>.</citation></ref>
<ref id="bibr46-0962280211432210"><label>46</label><citation citation-type="other"><comment>Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_152_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_152_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr47-0962280211432210"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simeon</surname><given-names>JG</given-names></name><name><surname>Dinicola</surname><given-names>VF</given-names></name><name><surname>Ferguson</surname><given-names>HB</given-names></name><name><surname>Copping</surname><given-names>W</given-names></name></person-group>. <article-title>Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <year>1990</year>; <volume>14</volume>: <fpage>791</fpage>–<lpage>795</lpage>.</citation></ref>
<ref id="bibr48-0962280211432210"><label>48</label><citation citation-type="other"><comment>Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_153_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_153_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr49-0962280211432210"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Weinberg</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression</article-title>. <source>Arch Gen Psychiatry</source> <year>1997</year>; <volume>54</volume>: <fpage>1031</fpage>–<lpage>1037</lpage>.</citation></ref>
<ref id="bibr50-0962280211432210"><label>50</label><citation citation-type="other"><comment>Eli Lilly. Fuoxetine versus placebo in childhood/adolescent depression, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_154_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_154_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr51-0962280211432210"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Heiligenstein</surname><given-names>JH</given-names></name><name><surname>Wagner</surname><given-names>KD</given-names></name><etal/></person-group>. <article-title>Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2002</year>; <volume>41</volume>: <fpage>1205</fpage>–<lpage>1215</lpage>.</citation></ref>
<ref id="bibr52-0962280211432210"><label>52</label><citation citation-type="other"><comment>Eli Lilly. Fluoxetine versus placebo in the treatment of children and adolescents with obsessive-compulsive disorder, <ext-link ext-link-type="uri" xlink:href="http://pdf.clinicalstudyresults.org/documents/company-study_155_0.pdf">http://pdf.clinicalstudyresults.org/documents/company-study_155_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr53-0962280211432210"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>DA</given-names></name><name><surname>Hoog</surname><given-names>SL</given-names></name><name><surname>Heiligenstein</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2001</year>; <volume>40</volume>: <fpage>773</fpage>–<lpage>779</lpage>.</citation></ref>
<ref id="bibr54-0962280211432210"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>March</surname><given-names>JS</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Wolkow</surname><given-names>R</given-names></name><name><surname>Safferman</surname><given-names>A</given-names></name><name><surname>Mardekian</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial</article-title>. <source>JAMA</source> <year>1998</year>; <volume>280</volume>(<issue>20</issue>): <fpage>1752</fpage>–<lpage>1756</lpage>.</citation></ref>
<ref id="bibr55-0962280211432210"><label>55</label><citation citation-type="other"><comment>Pfizer. Written testimony of Pfizer Inc submitted to the House Committee on Energy and Commerce Subcommittee on oversight and investigations regarding Zoloft studies in the pediatric population, <ext-link ext-link-type="uri" xlink:href="http://archives.energycommerce.house.gov/reparchives/108/Hearings/09092004hearing1351/Clary2207.htm">http://archives.energycommerce.house.gov/reparchives/108/Hearings/09092004hearing1351/Clary2207.htm</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr56-0962280211432210"><label>56</label><citation citation-type="other"><comment>Pfizer. A multi-center 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_98_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_98_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr57-0962280211432210"><label>57</label><citation citation-type="other"><comment>Pfizer. Two multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient studies of sertraline in children and adolescents with major depressive disorder combined, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_98_1.pdf">http://www.clinicalstudyresults.org/documents/company-study_98_1.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr58-0962280211432210"><label>58</label><citation citation-type="other"><comment>MHRA. Selective Serotonin Reuptake Inhibitors (SSRIs): overview of regulatory status and CSM advice relating to Major Depressive Disorder (MDD) in children and adolescents including a summary of available safety and efficacy data, <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk/PrintPreview/DefaultSP/CON019494">http://www.mhra.gov.uk/PrintPreview/DefaultSP/CON019494</ext-link> (2005, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr59-0962280211432210"><label>59</label><citation citation-type="other"><comment>Pfizer. A multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder, <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/documents/company-study_1981_0.pdf">http://www.clinicalstudyresults.org/documents/company-study_1981_0.pdf</ext-link> (2004, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr60-0962280211432210"><label>60</label><citation citation-type="other"><comment>GSK. A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression- acute phase, <ext-link ext-link-type="uri" xlink:href="http://www.gsk.com/media/paroxetine/depression_329_full.pdf">http://www.gsk.com/media/paroxetine/depression_329_full.pdf</ext-link> (1998, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr61-0962280211432210"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MB</given-names></name><name><surname>Ryan</surname><given-names>ND</given-names></name><name><surname>Strober</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>RG</given-names></name><name><surname>Kutcher</surname><given-names>SP</given-names></name><name><surname>Birmaher</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2001</year>; <volume>40</volume>: <fpage>762</fpage>–<lpage>772</lpage>.</citation></ref>
<ref id="bibr62-0962280211432210"><label>62</label><citation citation-type="other"><comment>GSK. A double-blind, multicentre placebo controlled study of paroxetine in adolescents with unipolar major depression, <ext-link ext-link-type="uri" xlink:href="http://www.gsk.com/media/paroxetine/depression_377_full.pdf">http://www.gsk.com/media/paroxetine/depression_377_full.pdf</ext-link> (1998, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr63-0962280211432210"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berard</surname><given-names>R</given-names></name><name><surname>Fong</surname><given-names>R</given-names></name><name><surname>Carpenter</surname><given-names>DJ</given-names></name><name><surname>Thomason</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>C</given-names></name></person-group>. <article-title>An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder</article-title>. <source>J Child Adolesc Psychopharmacol</source> <year>2006</year>; <volume>16</volume>: <fpage>59</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr64-0962280211432210"><label>64</label><citation citation-type="other"><comment>GSK. A 16 week double-blind, placebo controlled study to investigate the efficacy and tolerability of paroxetine in the treatment of children and adolescents with social anxiety disorder/social phobia, <ext-link ext-link-type="uri" xlink:href="http://www.gsk.com/media/paroxetine/sad_676_full.pdf">http://www.gsk.com/media/paroxetine/sad_676_full.pdf</ext-link>) (2002, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr65-0962280211432210"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Berard</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder</article-title>. <source>Arch Gen Psychiatry</source> <year>2004</year>; <volume>61</volume>: <fpage>1153</fpage>–<lpage>1162</lpage>.</citation></ref>
<ref id="bibr66-0962280211432210"><label>66</label><citation citation-type="other"><comment>GSK. A randomized, multicenter, 8-week, double-blind, placebo-controlled flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder, <ext-link ext-link-type="uri" xlink:href="http://www.gsk.com/media/paroxetine/depression_701_full.pdf">http://www.gsk.com/media/paroxetine/depression_701_full.pdf</ext-link> (2001, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr67-0962280211432210"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Kutcher</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, double-blind, placebo-controlled trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2006</year>; <volume>45</volume>: <fpage>709</fpage>–<lpage>719</lpage>.</citation></ref>
<ref id="bibr68-0962280211432210"><label>68</label><citation citation-type="other"><comment>GSK. A randomized, multicenter, 10-week, double-blind, placebo-controlled, flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), <ext-link ext-link-type="uri" xlink:href="http://www.gsk.com/media/paroxetine/ocd_704_full.pdf">http://www.gsk.com/media/paroxetine/ocd_704_full.pdf</ext-link> (2001, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr69-0962280211432210"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>DA</given-names></name><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Emslie</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2004</year>; <volume>43</volume>: <fpage>1387</fpage>–<lpage>1396</lpage>.</citation></ref>
<ref id="bibr70-0962280211432210"><label>70</label><citation citation-type="other"><comment>FDA. Clinical review of luvox (fluvoxamine). NDA 20-243 pediatric supplement S-021, <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-243S021.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-243S021.pdf</ext-link> (2000, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr71-0962280211432210"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riddle</surname><given-names>MA</given-names></name><name><surname>Reeve</surname><given-names>EA</given-names></name><name><surname>Yaryura-Tobias</surname><given-names>JA</given-names></name><name><surname>Yang</surname><given-names>HM</given-names></name><name><surname>Claghorn</surname><given-names>JL</given-names></name><name><surname>Gaffney</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2001</year>; <volume>40</volume>: <fpage>222</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr72-0962280211432210"><label>72</label><citation citation-type="other"><comment>FDA. Review and evaluation of clinical data for celexa. (citalopram hydrocloride). NDA 20-822 pediatric supplement SE5-016, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162562.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162562.pdf</ext-link>) (2002, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr73-0962280211432210"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KD</given-names></name><name><surname>Jonas</surname><given-names>J</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Ventura</surname><given-names>D</given-names></name><name><surname>Saikali</surname><given-names>K</given-names></name></person-group>. <article-title>A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <year>2006</year>; <volume>45</volume>: <fpage>280</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr74-0962280211432210"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Knorring</surname><given-names>AL</given-names></name><name><surname>Olsson</surname><given-names>GI</given-names></name><name><surname>Thomsen</surname><given-names>PH</given-names></name><name><surname>Lemming</surname><given-names>OM</given-names></name><name><surname>Hulten</surname><given-names>A</given-names></name></person-group>. <article-title>A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder</article-title>. <source>J Clin Psychopharmacol</source> <year>2006</year>; <volume>26</volume>: <fpage>311</fpage>–<lpage>315</lpage>.</citation></ref>
<ref id="bibr75-0962280211432210"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casat</surname><given-names>CD</given-names></name><name><surname>Pleasants</surname><given-names>DZ</given-names></name><name><surname>Van Wyck Fleet</surname><given-names>J</given-names></name></person-group>. <article-title>A double-blind trial of bupropion in children with attention deficit disorder</article-title>. <source>Psychopharmacol Bull</source> <year>1987</year>; <volume>23</volume>(<issue>1</issue>): <fpage>120</fpage>–<lpage>122</lpage>.</citation></ref>
<ref id="bibr76-0962280211432210"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conners</surname><given-names>CK</given-names></name><name><surname>Casat</surname><given-names>CD</given-names></name><name><surname>Gualtieri</surname><given-names>CT</given-names></name><name><surname>Weller</surname><given-names>E</given-names></name><name><surname>Reader</surname><given-names>M</given-names></name><name><surname>Reiss</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Bupropion hydrochloride in attention deficit disorder with hyperactivity</article-title>. <source>J Am Acad Adolesc Psychiatry</source> <year>1996</year>; <volume>34</volume>(<issue>10</issue>): <fpage>1314</fpage>–<lpage>1321</lpage>.</citation></ref>
<ref id="bibr77-0962280211432210"><label>77</label><citation citation-type="other"><comment>FDA. Clinical review for effexor XR. NDA 20-151 paediatric supplement SE5-024, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163132.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163132.pdf</ext-link> (2003, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr78-0962280211432210"><label>78</label><citation citation-type="other"><comment>FDA. Review and evaluation of clinical data: nefazodone hydrochloride (serzone). NDA: 20-152 pediatric supplement S-032, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164073.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164073.pdf</ext-link> (2002, accessed 24 October 2011)</comment>.</citation></ref>
<ref id="bibr79-0962280211432210"><label>79</label><citation citation-type="other"><comment>FDA. Review and evaluation of clinical data: mirtazapine (remeron). NDA 20-415 pediatric supplement SE5-011, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf</ext-link>) (2001, accessed 24 October 2011)</comment>.</citation></ref>
</ref-list><app-group><app id="app1-0962280211432210"><title>Appendix</title>
<sec id="sec15-0962280211432210"><title>Supporting analyses for the article</title>
<p>
<table-wrap id="table6-0962280211432210" position="float"><label>Table A1.</label><caption><p>Suicidal data from the individual studies</p></caption><graphic alternate-form-of="table6-0962280211432210" xlink:href="10.1177_0962280211432210-table6.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th rowspan="2">Drug</th><th rowspan="2">Study</th><th colspan="2">Number of patients</th><th colspan="2">Number of males</th><th colspan="2">Suicidal behaviour</th><th colspan="2">Suicidal ideation</th><th colspan="2">Suicidal behaviour or ideation</th><th rowspan="2">Source</th>
</tr>
<tr><th>Drug</th><th>Placebo</th><th>Drug</th><th>Placebo</th><th>Drug</th><th>Placebo</th><th>Drug</th><th>Placebo</th><th>Drug</th><th>Placebo</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Fluoxetine</td>
<td>HCCJ</td>
<td>21</td>
<td>19</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>X065</td>
<td>48</td>
<td>48</td>
<td>54</td>
<td>54</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>HCJE</td>
<td>109</td>
<td>110</td>
<td>55</td>
<td>56</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>HCJW</td>
<td>71</td>
<td>32</td>
<td>34</td>
<td>15</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>TADS</td>
<td>109</td>
<td>112</td>
<td>50</td>
<td>56</td>
<td>2</td>
<td>0</td>
<td>7</td>
<td>4</td>
<td>9</td>
<td>4</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; March et al.<sup><xref ref-type="bibr" rid="bibr30-0962280211432210">30</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Liebowitz</td>
<td>21</td>
<td>22</td>
<td>12</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; Liebowitz et al.<sup><xref ref-type="bibr" rid="bibr38-0962280211432210">38</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Birmaher</td>
<td>37</td>
<td>37</td>
<td>20</td>
<td>20</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; Birmaher<sup><xref ref-type="bibr" rid="bibr39-0962280211432210">39</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>498</td>
<td>92</td>
<td>95</td>
<td>52</td>
<td>47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>1001</td>
<td>97</td>
<td>91</td>
<td>44</td>
<td>49</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>1017</td>
<td>92</td>
<td>93</td>
<td>37</td>
<td>53</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>MH64089</td>
<td>133</td>
<td>76</td>
<td>75</td>
<td>39</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>Walkup et al.<sup><xref ref-type="bibr" rid="bibr40-0962280211432210">40</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>501061</td>
<td>67</td>
<td>62</td>
<td>27</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>Pfizer<sup><xref ref-type="bibr" rid="bibr31-0962280211432210">31</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>501033</td>
<td>15</td>
<td>10</td>
<td>6</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>Pfizer<sup><xref ref-type="bibr" rid="bibr32-0962280211432210">32</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>POTS</td>
<td>28</td>
<td>28</td>
<td>17</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp;POTS<sup><xref ref-type="bibr" rid="bibr37-0962280211432210">37</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>Rynn</td>
<td>11</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; Rynn<sup><xref ref-type="bibr" rid="bibr29-0962280211432210">29</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>329</td>
<td>93</td>
<td>88</td>
<td>35</td>
<td>30</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>377</td>
<td>180</td>
<td>95</td>
<td>59</td>
<td>33</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>6</td>
<td>2</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>676</td>
<td>165</td>
<td>156</td>
<td>71</td>
<td>89</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>701</td>
<td>104</td>
<td>102</td>
<td>54</td>
<td>55</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>704</td>
<td>99</td>
<td>107</td>
<td>53</td>
<td>66</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>114.02.01</td>
<td>57</td>
<td>63</td>
<td>29</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>RUPP</td>
<td>63</td>
<td>65</td>
<td>32</td>
<td>33</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; RUPP et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432210">41</xref></sup></td>
</tr>
<tr>
<td>Citalopram</td>
<td>CIT-MD-18</td>
<td>93</td>
<td>85</td>
<td>45</td>
<td>39</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Citalopram</td>
<td>94404</td>
<td>124</td>
<td>120</td>
<td>32</td>
<td>32</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>9</td>
<td>5</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SCT-MD-15</td>
<td>133</td>
<td>131</td>
<td>63</td>
<td>64</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td align="justify">Forest<sup><xref ref-type="bibr" rid="bibr42-0962280211432210">42</xref></sup> &amp; Wagner et al.<sup><xref ref-type="bibr" rid="bibr43-0962280211432210">43</xref></sup></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SCT-MD-32</td>
<td>155</td>
<td>157</td>
<td>63</td>
<td>65</td>
<td>6</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>6</td>
<td>7</td>
<td>Forest<sup><xref ref-type="bibr" rid="bibr44-0962280211432210">44</xref></sup></td>
</tr>
<tr>
<td>Bupropion</td>
<td>75</td>
<td>72</td>
<td>37</td>
<td>65</td>
<td>33</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>382</td>
<td>80</td>
<td>85</td>
<td>44</td>
<td>38</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>394</td>
<td>102</td>
<td>94</td>
<td>58</td>
<td>55</td>
<td>1</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>396</td>
<td>80</td>
<td>84</td>
<td>52</td>
<td>38</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>397</td>
<td>77</td>
<td>79</td>
<td>47</td>
<td>47</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>March</td>
<td>140</td>
<td>150</td>
<td>44</td>
<td>43</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td align="justify">Bridge et al.<sup><xref ref-type="bibr" rid="bibr12-0962280211432210">12</xref></sup> &amp; March et al.<sup><xref ref-type="bibr" rid="bibr45-0962280211432210">45</xref></sup></td>
</tr>
<tr>
<td>Nefazodone</td>
<td>CN104141</td>
<td>95</td>
<td>95</td>
<td>44</td>
<td>33</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Nefazodone</td>
<td>CN104187</td>
<td>184</td>
<td>94</td>
<td>94</td>
<td>47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>45</td>
<td>45</td>
<td>170</td>
<td>89</td>
<td>85</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr1-0962280211432210">1</xref></sup></td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table7-0962280211432210" position="float"><label>Table A2.</label><caption><p>Efficacy data from the individual studies</p></caption><graphic alternate-form-of="table7-0962280211432210" xlink:href="10.1177_0962280211432210-table7.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th rowspan="2">Drug</th><th rowspan="2">Study</th><th colspan="2">Efficacy outcome</th><th rowspan="2">Difference</th><th rowspan="2">Standard deviation</th><th colspan="2">Number of patients</th><th rowspan="2">Standardised difference</th><th rowspan="2">Outcome</th><th rowspan="2">Comment</th><th rowspan="2">Source</th>
</tr>
<tr><th>Drug</th><th>Placebo</th><th>Drug</th><th>Placebo</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Fluoxetine</td>
<td>HCCJ</td>
<td>−13.91</td>
<td>−12.42</td>
<td>−1.49</td>
<td>7.56</td>
<td>21</td>
<td>19</td>
<td>−0.20</td>
<td>HAM-D</td>
<td align="justify">Eli Lilly<sup><xref ref-type="bibr" rid="bibr46-0962280211432210">46</xref></sup> &amp; Simeon et al.<sup><xref ref-type="bibr" rid="bibr47-0962280211432210">47</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>X065</td>
<td>−20.20</td>
<td>−10.50</td>
<td>−9.70</td>
<td>14.74</td>
<td>48</td>
<td>47</td>
<td>−0.66</td>
<td>CDRS-R</td>
<td align="justify">Eli Lilly<sup><xref ref-type="bibr" rid="bibr48-0962280211432210">48</xref></sup> &amp; Emslie et al.<sup><xref ref-type="bibr" rid="bibr49-0962280211432210">49</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>HCJE</td>
<td>−22.10</td>
<td>−14.90</td>
<td>−7.20</td>
<td>13.87</td>
<td>109</td>
<td>105</td>
<td>−0.52</td>
<td>CDRS-R</td>
<td align="justify">Eli Lilly<sup><xref ref-type="bibr" rid="bibr50-0962280211432210">50</xref></sup> &amp; Emslie et al.<sup><xref ref-type="bibr" rid="bibr51-0962280211432210">51</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>HCJW</td>
<td>−9.50</td>
<td>−5.20</td>
<td>−4.30</td>
<td>8.69</td>
<td>71</td>
<td>32</td>
<td>−0.49</td>
<td>CY-BOCS</td>
<td align="justify">Eli Lilly<sup><xref ref-type="bibr" rid="bibr52-0962280211432210">52</xref></sup> &amp; Geller et al.<sup><xref ref-type="bibr" rid="bibr53-0962280211432210">53</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>TADS</td>
<td>−22.64</td>
<td>−19.41</td>
<td>−3.23</td>
<td>8.09</td>
<td>109</td>
<td>112</td>
<td>−0.40</td>
<td>CDRS-R</td>
<td align="justify">Only overall ages (<xref ref-type="table" rid="table3-0962280211432210">Table A3</xref>)</td>
<td>March et al.<sup><xref ref-type="bibr" rid="bibr30-0962280211432210">30</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Liebowitz</td>
<td>−7.79</td>
<td>−5.27</td>
<td>−2.52</td>
<td>10.09</td>
<td>21</td>
<td>12</td>
<td>−0.25</td>
<td>CY-BOCS</td>
<td>Liebowitz et al.<sup><xref ref-type="bibr" rid="bibr38-0962280211432210">38</xref></sup></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Birmaher</td>
<td>0.61</td>
<td>0.35</td>
<td>−0.26</td>
<td>0.48</td>
<td>37</td>
<td>37</td>
<td>−0.54</td>
<td>PARS</td>
<td>Binary response</td>
<td>Birmaher et al.<sup><xref ref-type="bibr" rid="bibr39-0962280211432210">39</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>498</td>
<td>−6.80</td>
<td>−3.40</td>
<td>−3.40</td>
<td>8.72</td>
<td>92</td>
<td>95</td>
<td>−0.39</td>
<td>CY-BOCS</td>
<td>March et al.<sup><xref ref-type="bibr" rid="bibr54-0962280211432210">54</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>1001</td>
<td>−25.90</td>
<td>−22.10</td>
<td>−3.80</td>
<td>14.79</td>
<td>93</td>
<td>88</td>
<td>−0.26</td>
<td>CDRS-R</td>
<td align="justify">SD from <italic>p</italic>-value in FDA submission</td>
<td align="justify">Pfizer,<sup><xref ref-type="bibr" rid="bibr55-0962280211432210">55</xref></sup> Pfizer,<sup><xref ref-type="bibr" rid="bibr56-0962280211432210">56</xref></sup> Pfizer,<sup><xref ref-type="bibr" rid="bibr57-0962280211432210">57</xref></sup> MHRA<sup><xref ref-type="bibr" rid="bibr58-0962280211432210">58</xref></sup> and Wagner<sup><xref ref-type="bibr" rid="bibr21-0962280211432210">21</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>1017</td>
<td>−28.80</td>
<td>−25.80</td>
<td>−3.00</td>
<td>18.40</td>
<td>92</td>
<td>91</td>
<td>−0.16</td>
<td>CDRS-R</td>
<td align="justify">SD from <italic>p</italic>-value in FDA submission</td>
<td align="justify">Pfizer,<sup><xref ref-type="bibr" rid="bibr55-0962280211432210">55</xref></sup> Pfizer,<sup><xref ref-type="bibr" rid="bibr57-0962280211432210">57</xref></sup> Pfizer,<sup><xref ref-type="bibr" rid="bibr59-0962280211432210">59</xref></sup> MHRA<sup><xref ref-type="bibr" rid="bibr58-0962280211432210">58</xref></sup> &amp; Wagner et al.<sup><xref ref-type="bibr" rid="bibr21-0962280211432210">21</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>MH64089</td>
<td>−9.00</td>
<td>−8.10</td>
<td>−0.90</td>
<td>6.15</td>
<td>133</td>
<td>76</td>
<td>−0.16</td>
<td>PARS</td>
<td>Walkup et al.<sup><xref ref-type="bibr" rid="bibr40-0962280211432210">40</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>501061</td>
<td>−17.00</td>
<td>−20.30</td>
<td>3.30</td>
<td>13.80</td>
<td>63</td>
<td>54</td>
<td>0.24</td>
<td align="justify">UCLA PTSD Index</td>
<td>Recruitment curtailed</td>
<td>Pfizer<sup><xref ref-type="bibr" rid="bibr31-0962280211432210">31</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>501033</td>
<td>−1.80</td>
<td>−1.11</td>
<td>−0.70</td>
<td>1.27</td>
<td>15</td>
<td>9</td>
<td>−0.55</td>
<td>CY-BOCS</td>
<td>Recruitment curtailed</td>
<td>Pfizer<sup><xref ref-type="bibr" rid="bibr32-0962280211432210">32</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>POTS</td>
<td>−7.00</td>
<td>−3.70</td>
<td>−3.30</td>
<td>7.25</td>
<td>28</td>
<td>28</td>
<td>−0.46</td>
<td>CY-BOCS</td>
<td>POTS<sup><xref ref-type="bibr" rid="bibr37-0962280211432210">37</xref></sup></td>
</tr>
<tr>
<td>Sertraline</td>
<td>Rynn</td>
<td>−12.80</td>
<td>−2.30</td>
<td>−10.50</td>
<td>6.75</td>
<td>11</td>
<td>11</td>
<td>−1.56</td>
<td>HAM-A</td>
<td align="justify">Only overall ages (<xref ref-type="table" rid="table3-0962280211432210">Table A3</xref>)</td>
<td>Rynn<sup><xref ref-type="bibr" rid="bibr29-0962280211432210">29</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>329</td>
<td>−10.74</td>
<td>−9.09</td>
<td>−1.80</td>
<td>7.71</td>
<td>90</td>
<td>87</td>
<td>−0.23</td>
<td>HAM-D</td>
<td align="justify">GSK<sup><xref ref-type="bibr" rid="bibr60-0962280211432210">60</xref></sup> &amp; Keller et al.<sup><xref ref-type="bibr" rid="bibr61-0962280211432210">61</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>377</td>
<td>−13.60</td>
<td>−12.80</td>
<td>−0.80</td>
<td>10.61</td>
<td>177</td>
<td>91</td>
<td>−0.08</td>
<td>MADRS</td>
<td>Binary ignored</td>
<td align="justify">GSK<sup><xref ref-type="bibr" rid="bibr62-0962280211432210">62</xref></sup> &amp; Berard et al.<sup><xref ref-type="bibr" rid="bibr63-0962280211432210">63</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>676</td>
<td>2.09</td>
<td>1.14</td>
<td>−0.95</td>
<td>1.32</td>
<td>162</td>
<td>154</td>
<td>−0.72</td>
<td align="justify">CGI – global improvement</td>
<td>Binary ignored</td>
<td align="justify">GSK<sup><xref ref-type="bibr" rid="bibr64-0962280211432210">64</xref></sup> &amp; Wagner et al.<sup><xref ref-type="bibr" rid="bibr65-0962280211432210">65</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>701</td>
<td>−22.60</td>
<td>−23.40</td>
<td>0.80</td>
<td>14.14</td>
<td>101</td>
<td>102</td>
<td>0.06</td>
<td>CDRS-R</td>
<td align="justify">GSK<sup><xref ref-type="bibr" rid="bibr66-0962280211432210">66</xref></sup> &amp; Emslie et al.<sup><xref ref-type="bibr" rid="bibr67-0962280211432210">67</xref></sup></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>704</td>
<td>−8.80</td>
<td>−5.30</td>
<td>−3.50</td>
<td>7.71</td>
<td>94</td>
<td>102</td>
<td>−0.45</td>
<td>CY-BOCS</td>
<td align="justify">GSK<sup><xref ref-type="bibr" rid="bibr68-0962280211432210">68</xref></sup> &amp; Geller et al.<sup><xref ref-type="bibr" rid="bibr69-0962280211432210">69</xref></sup></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>114.02.01</td>
<td>−6.00</td>
<td>−3.30</td>
<td>−2.70</td>
<td>8.55</td>
<td>57</td>
<td>63</td>
<td>−0.32</td>
<td>CY-BOCS</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr70-0962280211432210">70</xref></sup> &amp; Riddle et al.<sup><xref ref-type="bibr" rid="bibr71-0962280211432210">71</xref></sup></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>RUPP</td>
<td>−9.70</td>
<td>−3.10</td>
<td>−6.60</td>
<td>6.15</td>
<td>61</td>
<td>63</td>
<td>−1.07</td>
<td>PARS</td>
<td>RUPP et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432210">41</xref></sup></td>
</tr>
<tr>
<td>Citalopram</td>
<td>CIT-MD-18</td>
<td>−21.70</td>
<td>−16.50</td>
<td>−5.20</td>
<td>14.93</td>
<td>89</td>
<td>85</td>
<td>−0.35</td>
<td>CDRS-R</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr72-0962280211432210">72</xref></sup> &amp; Wagner et al.<sup><xref ref-type="bibr" rid="bibr73-0962280211432210">73</xref></sup></td>
</tr>
<tr>
<td>Citalopram</td>
<td>94404</td>
<td>−12.40</td>
<td>−12.70</td>
<td>0.30</td>
<td>12.15</td>
<td>124</td>
<td>120</td>
<td>0.02</td>
<td>K-SADS-P</td>
<td>No ITT information</td>
<td align="justify">MHRA<sup><xref ref-type="bibr" rid="bibr58-0962280211432210">58</xref></sup> &amp; Von Knorring<sup><xref ref-type="bibr" rid="bibr74-0962280211432210">74</xref></sup></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SCT-MD-15</td>
<td>−18.57</td>
<td>−20.30</td>
<td>−1.73</td>
<td>10.34</td>
<td>132</td>
<td>124</td>
<td>−0.17</td>
<td>CDRS-R</td>
<td align="justify">Active mean calculated from placebo plus the mean difference</td>
<td>Forest<sup><xref ref-type="bibr" rid="bibr42-0962280211432210">42</xref></sup> &amp; Wagner et al.<sup><xref ref-type="bibr" rid="bibr43-0962280211432210">43</xref></sup></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SCT-MD-32</td>
<td>21.80</td>
<td>−18.40</td>
<td>−3.40</td>
<td>9.77</td>
<td>154</td>
<td>157</td>
<td>−0.35</td>
<td>CDRS-R</td>
<td align="justify">Active mean calculated from placebo plus the mean difference</td>
<td>Forest<sup><xref ref-type="bibr" rid="bibr44-0962280211432210">44</xref></sup></td>
</tr>
<tr>
<td>Bupropion</td>
<td>75</td>
<td>−4.34</td>
<td>−3.38</td>
<td>−0.96</td>
<td>6.38</td>
<td>61</td>
<td>31</td>
<td>−0.15</td>
<td>CPQ</td>
<td>No ITT information</td>
<td align="justify">Casat et al.<sup><xref ref-type="bibr" rid="bibr75-0962280211432210">75</xref></sup> &amp; Conners et al.<sup><xref ref-type="bibr" rid="bibr76-0962280211432210">76</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>382</td>
<td>80</td>
<td>85</td>
<td>−0.15</td>
<td>CDRS-R</td>
<td align="justify">No ITT information, SD from <italic>p</italic>-value</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr77-0962280211432210">77</xref></sup> &amp; Emslie et al.<sup><xref ref-type="bibr" rid="bibr22-0962280211432210">22</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>394</td>
<td>102</td>
<td>94</td>
<td>−0.12</td>
<td>CDRS-R</td>
<td align="justify">No ITT information, SD from <italic>p</italic>-value</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr77-0962280211432210">77</xref></sup> &amp; Emslie et al.<sup><xref ref-type="bibr" rid="bibr22-0962280211432210">22</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>396</td>
<td>−15.50</td>
<td>−12.70</td>
<td>−2.80</td>
<td>9.68</td>
<td>78</td>
<td>82</td>
<td>−0.29</td>
<td align="justify">C-KIDDIE SADS GAD</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr77-0962280211432210">77</xref></sup> &amp; Rynn<sup><xref ref-type="bibr" rid="bibr23-0962280211432210">23</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>397</td>
<td>−18.70</td>
<td>−12.50</td>
<td>−6.20</td>
<td>10.10</td>
<td>76</td>
<td>77</td>
<td>−0.61</td>
<td align="justify">C-KIDDIE SADS GAD</td>
<td align="justify">FDA<sup><xref ref-type="bibr" rid="bibr77-0962280211432210">77</xref></sup> &amp; Rynn<sup><xref ref-type="bibr" rid="bibr23-0962280211432210">23</xref></sup></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>March</td>
<td>−18.90</td>
<td>−13.60</td>
<td>−5.30</td>
<td>10.35</td>
<td>148</td>
<td>137</td>
<td>−0.51</td>
<td>SAS-CA</td>
<td>March et al.<sup><xref ref-type="bibr" rid="bibr45-0962280211432210">45</xref></sup></td>
</tr>
<tr>
<td>Nefazodone</td>
<td>CN104141</td>
<td>−25.80</td>
<td>−22.10</td>
<td>−3.70</td>
<td>14.42</td>
<td>95</td>
<td>95</td>
<td>−0.26</td>
<td>CDRS-R</td>
<td align="justify">No ITT information, SD from <italic>p</italic>-value</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr78-0962280211432210">78</xref></sup></td>
</tr>
<tr>
<td>Nefazodone</td>
<td>CN104187</td>
<td>−21.90</td>
<td>−21.60</td>
<td>−0.30</td>
<td>9.76</td>
<td>180</td>
<td>93</td>
<td>−0.03</td>
<td>CDRS-R</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr78-0962280211432210">78</xref></sup></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>45</td>
<td>35.24</td>
<td>37.97</td>
<td>−2.74</td>
<td>13.73</td>
<td>165</td>
<td>85</td>
<td>−0.20</td>
<td>CDRS-R</td>
<td>FDA<sup><xref ref-type="bibr" rid="bibr79-0962280211432210">79</xref></sup></td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table8-0962280211432210" position="float"><label>Table A3.</label><caption><p>Back ground trial information from individual studies</p></caption><graphic alternate-form-of="table8-0962280211432210" xlink:href="10.1177_0962280211432210-table8.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th rowspan="2"/><th rowspan="2">Class</th><th rowspan="2">Study</th><th rowspan="2">Indication</th><th rowspan="2">Location</th><th rowspan="2">Number of centres</th><th align="center" colspan="2">Age</th><th rowspan="2">Year</th><th rowspan="2">Age range years</th><th rowspan="2">Study duration weeks</th><th rowspan="2">Protocol dose mg/day</th><th rowspan="2">From FDA analysis</th>
</tr>
<tr><th>Drug</th><th>Placebo</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>HCCJ</td>
<td>Major depressive disorder</td>
<td>Canada</td>
<td>1</td>
<td>15.95</td>
<td>15.16</td>
<td>1984</td>
<td>12–17</td>
<td>6</td>
<td>20–60</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>X065</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>1</td>
<td>12.67</td>
<td>13.00</td>
<td>1991</td>
<td>8–18</td>
<td>8</td>
<td>20</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>HCJE</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>16</td>
<td>12.70</td>
<td>12.69</td>
<td>1998</td>
<td>8–17</td>
<td>9</td>
<td>20 or 10</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>HCJW</td>
<td>Obsessive compulsive disorder</td>
<td>USA</td>
<td>21</td>
<td>11.42</td>
<td>11.41</td>
<td>1999</td>
<td>7–17</td>
<td>13</td>
<td>20–60</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>TADS</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>13</td>
<td>14.60</td>
<td>14.60</td>
<td>1998</td>
<td>12–17</td>
<td>12</td>
<td>10–40</td>
<td>No</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>Liebowitz</td>
<td>Obsessive compulsive disorder</td>
<td>USA</td>
<td>2</td>
<td>1991</td>
<td>6–18</td>
<td>8</td>
<td>20–80</td>
<td>No</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>Birmaher</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>1</td>
<td>1997</td>
<td>7–17</td>
<td>12</td>
<td>20</td>
<td>No</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>498</td>
<td>Obsessive compulsive disorder</td>
<td>USA</td>
<td>12</td>
<td>12.08</td>
<td>12.16</td>
<td>1994</td>
<td>6–17</td>
<td>12</td>
<td>25–200</td>
<td>Yes</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>1001</td>
<td>Major depressive disorder</td>
<td>India + USA</td>
<td>27</td>
<td>12.01</td>
<td>11.99</td>
<td>2001</td>
<td>6–17</td>
<td>10</td>
<td>50–200</td>
<td>Yes</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>1017</td>
<td>Major depressive disorder</td>
<td>India + North America</td>
<td>24</td>
<td>11.91</td>
<td>11.98</td>
<td>2001</td>
<td>6–17</td>
<td>10</td>
<td>50–200</td>
<td>Yes</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>MH64089</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>7</td>
<td>10.60</td>
<td>10.80</td>
<td>2003</td>
<td>7–17</td>
<td>12</td>
<td>25–200</td>
<td>No</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>501061</td>
<td>Post traumatic stress disorder</td>
<td>USA</td>
<td>30</td>
<td>10.80</td>
<td>11.20</td>
<td>2002</td>
<td>6–17</td>
<td>10</td>
<td>25–200</td>
<td>No</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>501033</td>
<td>Obsessive compulsive disorder</td>
<td>France</td>
<td>14</td>
<td>2002</td>
<td>6–17</td>
<td>39</td>
<td>25–200</td>
<td>No</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>POTS</td>
<td>Obsessive compulsive disorder</td>
<td>USA</td>
<td>56</td>
<td>11.70</td>
<td>12.30</td>
<td>1997</td>
<td>7–17</td>
<td>3</td>
<td>25–200</td>
<td>No</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>Rynn</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>1</td>
<td>11.70</td>
<td>11.70</td>
<td>5–17</td>
<td>9</td>
<td>50</td>
<td>No</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>329</td>
<td>Major depressive disorder</td>
<td>USA + Canada</td>
<td>12</td>
<td>14.80</td>
<td>15.09</td>
<td>1994</td>
<td>12–18</td>
<td>8</td>
<td>20–40</td>
<td>Yes</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>377</td>
<td>Major depressive disorder</td>
<td>Non-USA</td>
<td>32</td>
<td>15.50</td>
<td>15.83</td>
<td>1995</td>
<td>13–18</td>
<td>12</td>
<td>20–40</td>
<td>Yes</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>676</td>
<td>Social anxiety disorder</td>
<td>USA + Foreign</td>
<td>38</td>
<td>13.01</td>
<td>13.26</td>
<td>1999</td>
<td>8–17</td>
<td>16</td>
<td>10–50</td>
<td>Yes</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>701</td>
<td>Major depressive disorder</td>
<td>USA + Canada</td>
<td>41</td>
<td>11.92</td>
<td>12.15</td>
<td>2000</td>
<td>7–17</td>
<td>8</td>
<td>10–50</td>
<td>Yes</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>704</td>
<td>Obsessive compulsive disorder</td>
<td>USA + Canada</td>
<td>39</td>
<td>11.06</td>
<td>11.56</td>
<td>2000</td>
<td>7–17</td>
<td>10</td>
<td>10–50</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>SSRI</td>
<td>114.02.01</td>
<td>Obsessive compulsive disorder</td>
<td>USA</td>
<td>20</td>
<td>13.42</td>
<td>12.72</td>
<td>1991</td>
<td>8–17</td>
<td>10</td>
<td>50–200</td>
<td>Yes</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>SSRI</td>
<td>RUPP</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>5</td>
<td>10.40</td>
<td>10.30</td>
<td>1997</td>
<td>6–17</td>
<td>8</td>
<td>50–300</td>
<td>No</td>
</tr>
<tr>
<td>Citalopram</td>
<td>SSRI</td>
<td>CIT-MD-18</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>21</td>
<td>11.95</td>
<td>12.07</td>
<td>2000</td>
<td>7–17</td>
<td>8</td>
<td>20–40</td>
<td>Yes</td>
</tr>
<tr>
<td>Citalopram</td>
<td>SSRI</td>
<td>94404</td>
<td>Major depressive disorder</td>
<td>Europe</td>
<td>31</td>
<td>15.77</td>
<td>16.11</td>
<td>1996</td>
<td>13–18</td>
<td>12</td>
<td>10–40</td>
<td>Yes</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SSRI</td>
<td>SCT-MD-15</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>25</td>
<td>12.20</td>
<td>12.40</td>
<td>2002</td>
<td>6–17</td>
<td>8</td>
<td>10–20</td>
<td>No</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>SSRI</td>
<td>SCT-MD-32</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>40</td>
<td>14.70</td>
<td>14.50</td>
<td>2005</td>
<td>12–17</td>
<td>8</td>
<td>12–17</td>
<td>No</td>
</tr>
<tr>
<td>Bupropion</td>
<td>Atypical</td>
<td>75</td>
<td align="justify">Attention deficit hyperactivity disorder</td>
<td>USA</td>
<td>4</td>
<td>8.57</td>
<td>8.49</td>
<td>1983</td>
<td>6–12</td>
<td>4</td>
<td>150–250</td>
<td>Yes</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Atypical</td>
<td>382</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>14</td>
<td>12.16</td>
<td>12.21</td>
<td>1997</td>
<td>7–17</td>
<td>8</td>
<td>37.5–225</td>
<td>Yes</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Atypical</td>
<td>394</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>37</td>
<td>12.23</td>
<td>12.12</td>
<td>2000</td>
<td>7–17</td>
<td>8</td>
<td>37.5–225</td>
<td>Yes</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Atypical</td>
<td>396</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>37</td>
<td>11.38</td>
<td>11.11</td>
<td>2000</td>
<td>6–17</td>
<td>8</td>
<td>37.5–225</td>
<td>Yes</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Atypical</td>
<td>397</td>
<td>Generalised anxiety disorder</td>
<td>USA</td>
<td>29</td>
<td>11.65</td>
<td>11.29</td>
<td>2000</td>
<td>6–17</td>
<td>8</td>
<td>37.5–225</td>
<td>Yes</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Atypical</td>
<td>March</td>
<td>Social anxiety disorder</td>
<td>USA</td>
<td>44</td>
<td>13.60</td>
<td>13.60</td>
<td>2000</td>
<td>8–17</td>
<td>16</td>
<td>37.5–225</td>
<td>No</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>Atypical</td>
<td>CN104141</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>15</td>
<td>14.71</td>
<td>14.63</td>
<td>1998</td>
<td>12–17</td>
<td>8</td>
<td>100–600</td>
<td>Yes</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>Atypical</td>
<td>CN104187</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>28</td>
<td>11.89</td>
<td>12.39</td>
<td>2000</td>
<td>7–17</td>
<td>8</td>
<td>100–600</td>
<td>Yes</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>Atypical</td>
<td>45</td>
<td>Major depressive disorder</td>
<td>USA</td>
<td>34</td>
<td>12.08</td>
<td>12.37</td>
<td>1999</td>
<td>7–17</td>
<td>8</td>
<td>15–45</td>
<td>Yes</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table9-0962280211432210" position="float"><label>Table A4.</label><caption><p>Suicidal behaviour, ideation and possible suicidal behaviour, ideation results for SSRI and atypical treatments</p></caption><graphic alternate-form-of="table9-0962280211432210" xlink:href="10.1177_0962280211432210-table9.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th align="center" colspan="4">Active</th><th align="center" colspan="4">Placebo</th>
</tr>
<tr><th colspan="2"/><th>Sample size</th><th>Behaviour</th><th>Ideation</th><th>Behaviour or ideation</th><th>Sample size</th><th>Behaviour</th><th>Ideation</th><th>Behaviour or ideation</th>
</tr></thead>
<tbody align="left">
<tr>
<td>SSRI</td>
<td>Depression</td>
<td>1358</td>
<td>29 (0.02135)</td>
<td>22 (0.01620)</td>
<td>51 (0.03756)</td>
<td>1251</td>
<td>15 (0.01105)</td>
<td>20 (0.01473)</td>
<td>35 (0.02577)</td>
</tr>
<tr>
<td>Other</td>
<td>859</td>
<td>2 (0.00233)</td>
<td>9 (0.01048)</td>
<td>11 (0.01281)</td>
<td>764</td>
<td>1 (0.00116)</td>
<td>1 (0.00116)</td>
<td>2 (0.00233)</td>
</tr>
<tr>
<td align="justify">Group total</td>
<td>2217</td>
<td>31 (0.01398)</td>
<td>31 (0.01398)</td>
<td>62 (0.02797)</td>
<td>2015</td>
<td>16 (0.00722)</td>
<td>21 (0.00947)</td>
<td>37 (0.01669)</td>
</tr>
<tr>
<td>Atypical</td>
<td>Depression</td>
<td>631</td>
<td>1 (0.00158)</td>
<td>8 (0.01268)</td>
<td>9 (0.01426)</td>
<td>457</td>
<td>0 (0.00000)</td>
<td>0 (0.00000)</td>
<td>0 (0.00000)</td>
</tr>
<tr>
<td>Other</td>
<td>369</td>
<td>2 (0.00542)</td>
<td>2 (0.00542)</td>
<td>4 (0.01084)</td>
<td>350</td>
<td>2 (0.00542)</td>
<td>0 (0.00000)</td>
<td>2 (0.00542)</td>
</tr>
<tr>
<td align="justify">Group total</td>
<td>1000</td>
<td>3 (0.00300)</td>
<td>10 (0.01000)</td>
<td>13 (0.01300)</td>
<td>807</td>
<td>2 (0.00200)</td>
<td>0 (0.00000)</td>
<td>2 (0.00200)</td>
</tr>
<tr>
<td>Total</td>
<td>3217</td>
<td>34 (0.01057)</td>
<td>41 (0.01274)</td>
<td>75 (0.02331)</td>
<td>2822</td>
<td>18 (0.00560)</td>
<td>21 (0.00653)</td>
<td>39 (0.01212)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table10-0962280211432210" position="float"><label>Table A5.</label><caption><p>Suicidal behaviour, ideation and possible suicidal behaviour, ideation results for individual compounds for SSRI and atypical treatments from a meta-analysis</p></caption><graphic alternate-form-of="table10-0962280211432210" xlink:href="10.1177_0962280211432210-table10.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th colspan="2">Drug</th><th>Indication</th><th>Number of studies</th><th>Suicidal behaviour</th><th>Suicidal ideation</th><th>Suicidal behaviour or ideation</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="7"><italic>Panel A: SSRI</italic></td>
</tr>
<tr>
<td colspan="2" rowspan="3">Fluoxetine</td>
<td>Depression</td>
<td>4</td>
<td>0.00917 (−0.09068 to 0.10901)</td>
<td>0.00371 (−0.03687 to 0.04430)</td>
<td>0.01558 (−0.02678 to 0.05795)</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>0.00673 (−0.05759 to 0.07105)</td>
<td>0.00000 (−0.06295 to 0.06295)</td>
<td>0.00673 (−0.05759 to 0.07105)</td>
</tr>
<tr>
<td>Overall</td>
<td>7</td>
<td>0.00917 (−0.09068 to 0.10901)</td>
<td>0.00262 (−0.03149 to 0.03673)</td>
<td>0.01290 (−0.02248 to 0.04828)</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Sertraline</td>
<td>Depression</td>
<td>2</td>
<td>0.00133 (−0.03438 to 0.03704)</td>
<td>0.01551 (−0.01927 to 0.05028)</td>
<td>0.01676 (−0.02245 to 0.05597)</td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>−0.00395 (−0.03167 to 0.02377)</td>
<td>0.00251 (−0.02585 to 0.03087)</td>
<td>−0.00174 (−0.03113 to 0.02764)</td>
</tr>
<tr>
<td>Overall</td>
<td>8</td>
<td>−0.00196 (−0.02386 to 0.01993)</td>
<td>0.00770 (−0.01428 to 0.02968)</td>
<td>0.00491 (−0.01860 to 0.02843)</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Paroxetine</td>
<td>Depression</td>
<td>3</td>
<td>0.01556 (−0.01248 to 0.04361)</td>
<td>0.00150 (−0.02311 to 0.02612)</td>
<td>0.01588 (−0.01434 to 0.04610)</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>0.00000 (−0.02205 to 0.02205)</td>
<td>0.01534 (−0.01047 to 0.04115)</td>
<td>0.01534 (−0.01047 to 0.04115)</td>
</tr>
<tr>
<td>Overall</td>
<td>5</td>
<td>0.00595 (−0.01139 to 0.02328)</td>
<td>0.00809 (−0.00972 to 0.02591)</td>
<td>0.01557 (−0.00406 to 0.03519)</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Citalopram</td>
<td>Depression</td>
<td>2</td>
<td>0.01549 (−0.02202 to 0.05301)</td>
<td>−0.00617 (−0.04118 to 0.02883)</td>
<td>0.00665 (−0.03590 to 0.04921)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Escitalopram</td>
<td>Depression</td>
<td>2</td>
<td>−0.00175 (−0.03164 to 0.02814)</td>
<td>−0.00651 (−0.02874 to 0.01573)</td>
<td>−0.00703 (−0.03761 to 0.02354)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Fluvoxemine</td>
<td>Depression</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>0.00000 (−0.04626 to 0.04626)</td>
<td>0.01407 (−0.03505 to 0.06319)</td>
<td>0.01407 (−0.03505 to 0.06319)</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td colspan="7"><italic>Panel B: Atypical</italic></td>
</tr>
<tr>
<td colspan="2" rowspan="3">Bupropion</td>
<td>Depression</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td>0.00000 (−0.05843 to 0.10405)</td>
<td>0.00000 (−0.05843 to 0.10405)</td>
<td>0.00000 (−0.05843 to 0.10405)</td>
</tr>
<tr>
<td>Overall</td>
<td>1</td>
</tr>
<tr>
<td colspan="2">Venlafaxine</td>
<td>Depression</td>
<td>2</td>
<td>0.00537 (−0.02823 to 0.03897)</td>
<td>0.03846 (−0.00204 to 0.0789)</td>
<td>0.04371 (0.00215 to 0.08527)</td>
</tr>
<tr>
<td colspan="2"/>
<td>Other</td>
<td>3</td>
<td>0.00033 (−0.02493 to 0.02559)</td>
<td>0.00770 (−0.01699 to 0.03238)</td>
<td>0.00758 (−0.01944 to 0.03461)</td>
</tr>
<tr>
<td colspan="2"/>
<td>Overall</td>
<td>5</td>
<td>0.00215 (−0.01804 to 0.02234)</td>
<td>0.01603 (−0.00505 to 0.03711)</td>
<td>0.01832 (−0.00434 to 0.04097)</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Nefazodone</td>
<td>Depression</td>
<td>2</td>
<td>0.00000 (−0.02667 to 0.02667)</td>
<td>0.00000 (−0.02667 to 0.02667)</td>
<td>0.00000 (−0.02667 to 0.02667)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td colspan="2" rowspan="3">Mertazapine</td>
<td>Depression</td>
<td>1</td>
<td>0.000000 (−0.02549 to 0.04610)</td>
<td>0.005882 (−0.02338 to 0.05192)</td>
<td>0.005882 (−0.02338 to 0.05192)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>1</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table11-0962280211432210" position="float"><label>Table A6.</label><caption><p>Overall suicidal behaviour, ideation and ideation and suicide results for SSRI and atypical treatments from a meta-analysis – sensitivity analysis omitting studies with no events (absolute risk differences and 95% confidence intervals)</p></caption><graphic alternate-form-of="table11-0962280211432210" xlink:href="10.1177_0962280211432210-table11.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th align="center" colspan="3">Indication</th>
</tr>
<tr><th align="center">Depression</th><th align="center">Other</th><th align="center">Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><italic>Panel A: Suicidal behaviour</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00939 (−0.00542 to 0.02421)</td>
<td>−0.00597 (−0.04721 to 0.03527)</td>
<td>0.00764 (−0.00631 to 0.02158)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.009804 (−0.03716 to 0.05365)*</td>
<td>0.00044 (−0.02878 to 0.02966)</td>
<td>0.00764 (−0.00631 to 0.02158)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00943 (−0.00465 to 0.02352)</td>
<td>−0.00170 (−0.02554 to 0.02214)</td>
<td>0.00588 (−0.00561 to 0.01736)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel B: Suicidal ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>−0.00013 (−0.01441 to 0.01415)</td>
<td>0.01400 (−0.00693 to 0.03492)</td>
<td>0.00436 (−0.00744 to 0.01616)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.02098 (−0.00659 to 0.04856)</td>
<td>0.014286 (−0.02398 to 0.04328)*</td>
<td>0.01829 (−0.00303 to 0.03961)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00434 (−0.00835 to 0.01051)</td>
<td>0.00857 (−0.00049 to 0.01763)</td>
<td>0.00690 (−0.00292 to 0.01671)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel C: Suicidal behaviour or ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00844 (−0.00752 to 0.02439)</td>
<td>0.00991 (−0.00875 to 0.02857)</td>
<td>0.00906 (−0.00307 to 0.02118)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.02293 (−0.00497 to 0.05083</td>
<td>0.01067 (−0.02138 to 0.04273)</td>
<td>0.01765 (−0.00340 to 0.03869)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.01201 (−0.00184 to 0.02586)</td>
<td>0.01010 (−0.00602 to 0.02623)</td>
<td>0.01120 (0.00069 to 0.02170)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-09622802114322"><label>*</label><p>one study only.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table12-0962280211432210" position="float"><label>Table A7.</label><caption><p>Overall suicidal behaviour, ideation and ideation and suicide results for SSRI and atypical treatments from a meta-analysis – sensitivity analysis with amended weights (absolute risk differences and 95% confidence intervals)</p></caption><graphic alternate-form-of="table12-0962280211432210" xlink:href="10.1177_0962280211432210-table12.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th align="center" colspan="3">Indication</th>
</tr>
<tr><th>Depression</th><th>Other</th><th>Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><italic>Panel A: Suicidal behaviour</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00853 (0.00066 to 0.01640)</td>
<td>−0.00086 (−0.00855 to 0.00682)</td>
<td>0.00422 (−0.00086 to 0.00930)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.00155 (−0.00729 to 0.01039)</td>
<td>0.00030 (−0.01152 to 0.01212)</td>
<td>0.00110 (−0.00568 to 0.00818)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00577 (0.00030 to 0.01125)</td>
<td>−0.00052 (−0.00696 to 0.00592)</td>
<td>0.00316 (−0.00097 to 0.00728)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel B: Suicidal ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>−0.00011 (−0.00860 to 0.00838)</td>
<td>0.00937 (−0.00181 to 0.02056)</td>
<td>0.00336 (−0.00341 to 0.01012)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01185 (−0.00366 to 0.02736)</td>
<td>0.00705 (−0.0838 to 0.02254)</td>
<td>0.00891 (−0.00081 to 0.01864)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.00312 (−0.00391 to 0.01387)</td>
<td>0.00857 (−0.00529 to 0.02243)</td>
<td>0.00517 (−0.00038 to 0.01072)</td>
</tr>
<tr>
<td colspan="4"><italic>Panel C: Suicidal behaviour or ideation</italic></td>
</tr>
<tr>
<td>SSRI</td>
<td>0.00844 (−0.00276 to 0.01993)</td>
<td>0.00859 (−0.00878 to 0.02595)</td>
<td>0.00850 (0.00083 to 0.01618)</td>
</tr>
<tr>
<td>Atypical</td>
<td>0.01400 (−0.00381 to 0.0318)</td>
<td>0.00683 (−0.00992 to 0.02358)</td>
<td>0.00957 (−0.00075 to 0.01990)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.01002 (0.00130 to 0.01873)</td>
<td>0.00803 (−0.00136 to 0.0224)</td>
<td>0.00886 (0.00275 to 0.01496)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table13-0962280211432210" position="float"><label>Table A8.</label><caption><p>Efficacy results for individual compounds for SSRI and atypical treatments</p></caption><graphic alternate-form-of="table13-0962280211432210" xlink:href="10.1177_0962280211432210-table13.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th>Drug</th><th>Indication</th><th>Number of studies</th><th>Standardised difference (95% CI)</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><italic>Panel A: SSRI</italic></td>
</tr>
<tr>
<td rowspan="3">Fluoxetine</td>
<td>Depression</td>
<td>4</td>
<td>−0.47 (−0.64 to −0.31)</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>−0.47 (−0.75 to −0.19)</td>
</tr>
<tr>
<td>Overall</td>
<td>7</td>
<td>−0.47 (−0.62 to −0.33)</td>
</tr>
<tr>
<td rowspan="3">Sertraline</td>
<td>Depression</td>
<td>2</td>
<td>−0.21 (−0.42 to−0.004)</td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>−0.36 (−0.71 to −0.02)</td>
</tr>
<tr>
<td>Overall</td>
<td>8</td>
<td>−0.29 (−0.51 to −0.06)</td>
</tr>
<tr>
<td rowspan="3">Paroxetine</td>
<td>Depression</td>
<td>3</td>
<td>−0.08 (−0.23 to 0.08)</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>−0.60 (−0.86 to −0.34)</td>
</tr>
<tr>
<td>Overall</td>
<td>5</td>
<td>−0.29 (−0.58 to 0.003)</td>
</tr>
<tr>
<td rowspan="4">Citalopram</td>
<td>Depression</td>
<td>2</td>
<td>−0.14 (−0.54 to 0.26)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td rowspan="3">Escitalopram</td>
<td>Depression</td>
<td>2</td>
<td>−0.27 (−0.44 to−0.09)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td rowspan="3">Fluvoxemine</td>
<td>Depression</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>−0.70 (−1.43 to 0.04)</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td colspan="4"><italic>Panel B. Atypical</italic></td>
</tr>
<tr>
<td rowspan="3">Bupropion</td>
<td>Depression</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td>−0.15 (−0.58 to 0.28)</td>
</tr>
<tr>
<td>Overall</td>
<td>1</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>Depression</td>
<td>2</td>
<td>−0.13 (−0.34 to 0.07)</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>−0.48 (−0.64 to −0.31)</td>
</tr>
<tr>
<td>Overall</td>
<td>5</td>
<td>−0.34 (−0.53 to −0.15)</td>
</tr>
<tr>
<td rowspan="3">Nefazodone</td>
<td>Depression</td>
<td>2</td>
<td>−0.13 (−0.36 to 0.09)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>2</td>
</tr>
<tr>
<td rowspan="3">Mertazapine</td>
<td>Depression</td>
<td>1</td>
<td>−0.20 (−0.46 to 0.06)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Overall</td>
<td>1</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table14-0962280211432210" position="float"><label>Table A9.</label><caption><p>verall efficacy results for SSRI and atypical treatments – with outlying study dropped (standardised mean differences and 95% confidence intervals)</p></caption><graphic alternate-form-of="table14-0962280211432210" xlink:href="10.1177_0962280211432210-table14.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th align="center" colspan="4">Indication</th>
</tr>
<tr><th>Depression</th><th>Other</th><th colspan="2">Overall</th>
</tr></thead>
<tbody align="left">
<tr>
<td>SSRI</td>
<td>−0.43 (−0.63 to −0.24)</td>
<td colspan="2">−0.33 (−0.44 to −0.21)</td>
</tr>
<tr>
<td>Atypical</td>
</tr>
<tr>
<td>Overall</td>
<td>−0.43 (−0.57 to −0.28)</td>
<td colspan="2">−0.31 (−039 to −0.22)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig8-0962280211432210" position="float"><label>Figure A1.</label><caption><p>Normal probability plots from the sensitivity analysis of standardised residuals for suicidal behaviour results by suicidal outcome: (a) behaviour, (b) ideation and (c) behaviour or ideation.</p></caption><graphic xlink:href="10.1177_0962280211432210-fig8.tif"/></fig>
</p>
</sec></app></app-group>
</back>
</article>